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Résumé 
Les dynorphines sont des neuropeptides importants avec un rôle central dans la 
nociception et l’atténuation de la douleur. De nombreux mécanismes régulent les 
concentrations de dynorphine endogènes, y compris la protéolyse. Les Proprotéines 
convertases (PC) sont largement exprimées dans le système nerveux central et clivent 
spécifiquement le C-terminale de couple acides aminés basiques, ou un résidu basique 
unique. Le contrôle protéolytique des concentrations endogènes de Big Dynorphine (BDyn) 
et dynorphine A (Dyn A) a un effet important sur la perception de la douleur et le rôle de PC 
reste à être déterminée. L'objectif de cette étude était de décrypter le rôle de PC1 et PC2 dans 
le contrôle protéolytique de BDyn et Dyn A avec l'aide de fractions cellulaires de la moelle 
épinière de type sauvage (WT), PC1 -/+ et PC2 -/+ de souris et par la spectrométrie de masse. 
Nos résultats démontrent clairement que PC1 et PC2 sont impliquées dans la protéolyse de 
BDyn et Dyn A avec un rôle plus significatif pour PC1. Le traitement en C-terminal de BDyn 
génère des fragments peptidiques spécifiques incluant dynorphine 1-19, dynorphine 1-13, 
dynorphine 1-11 et dynorphine 1-7 et Dyn A génère les fragments dynorphine 1-13, 
dynorphine 1-11 et dynorphine 1-7. Ils sont tous des fragments de peptides associés à PC1 
ou PC2. En plus, la protéolyse de BDyn conduit à la formation de Dyn A et Leu-Enk, deux 
peptides opioïdes importants. La vitesse de formation des deux est réduite de manière 
significative dans les fractions cellulaires de la moelle épinière de souris mutantes. En 
conséquence, l'inhibition même partielle de PC1 ou PC2 peut altérer le système opioïde 
endogène. 
Mots-clés: Dynorphines, Dynorphine A, Proprotéines convertases, Protéolyse, Peptides 
opioïdes, Moelle épinière, Spectrométrie de masse, Douleur, Synapse. 
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Abstract 
Dynorphins are important neuropeptides with a central role in nociception and pain 
alleviation. Many mechanisms regulate endogenous dynorphin concentrations, including 
proteolysis. Proprotein convertases (PCs) are widely expressed in the central nervous system 
and specifically cleave at C-terminal of either a pair of basic amino acids, or a single basic 
residue. The proteolysis control of endogenous Big Dynorphin (BDyn) and Dynorphin A 
(Dyn A) levels has a profound impact on pain perception and the role of PCs remain unclear. 
The objective of this study was to decipher the role of PC1 and PC2 in the proteolysis control 
of BDyn and Dyn A levels using cellular fractions of spinal cords from wild type (WT), PC1-
/+ and PC2-/+ animals and mass spectrometry. Our results clearly demonstrate that both PC1 
and PC2 are involved in the proteolysis regulation of BDyn and Dyn A with a more important 
role for PC1. C-terminal processing of BDyn generates specific peptide fragments Dynorphin 
1-19, Dynorphin 1-13, Dynorphin 1-11 and Dynorphin 1-7 and C-terminal processing of Dyn 
A generates Dynorphin 1-13, Dynorphin 1-11 and Dynorphin 1-7, all these peptide fragments 
are associated with PC1 or PC2 processing. Moreover, proteolysis of BDyn leads to the 
formation of Dyn A and Leu-Enk, two important opioid peptides. The rate of formation of 
both is significantly reduced in cellular fractions of spinal cord mutant mice. As a 
consequence, even partial inhibition of PC1 or PC2 may impair the endogenous opioid 
system.   
Keywords: Dynorphins, Dynorphin A, Proprotein convertases, Proteolysis, Opioid 
peptides, Spinal cords, Mass spectrometry, Pain, Synapse. 
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Introduction 
Patients suffering from chronic or neuropathic pain have a highly compromised 
quality of life and account for approximately 20-25% of the population worldwide. Given 
the importance of managing pain in medicine, the complex mechanisms that encompass pain 
perception, transduction and modulations are currently subject of intense research. 
Pain is usually caused by a noxious stimulation of the peripheral nervous system 
(PNS). The PNS is responsible for perceiving those stimuli and to project that information 
through afferent neurons to the spinal cord. The synaptic transmission takes place at the 
external laminae of the dorsal root between afferent neurons and secondary order neurons. 
This process is called first synapse and regulates the intracellular signaling between the PNS 
and the central nervous system (CNS), relaying nociceptive information to the brain where it 
is perceived as pain. The communication between neurons is mediated by the release of 
excitatory neurotransmitters from the terminal of the afferent neurons. The neurotransmitters, 
like glutamate and substance P (SP), activate secondary neurons by their interaction with 
post-synaptic receptors such as N-methyl-D-aspartate (NMDA) and neurokinin-1 (NK1) 
receptors. When a noxious stimulus is perceived, the release of those excitatory 
neurotransmitters is enhanced. As a response to that perception, the brain is able to modulate 
the activity at first synapses through different modulatory pathways. The release of 
endogenous opioid peptides into the first synapse is the principal endogenous mechanism for 
the alleviation of pain. 
Four families of endogenous opioid peptides have been described to date. They 
include endorphins, endomorphins, enkephalins and dynorphins. These peptides are 
synthetized as large and inactive proneuropeptides and requires endoproteolytic processing 
to generate the bioactive peptides, which play an essential role in the endogenous modulation 
of pain. Several studies have shown that protein convertases (PCs), specifically PC1 and PC2, 
are involved into C-terminal endoproteolytic processing of proneuropeptides through their 
cleavage at basic residues of proteins and peptides. In neuronal cells, proneuropeptides and 
PCs are synthetized and packed into dense-core vesicles. During the axonal transport of these 
vesicles, proneuropeptides are processed by PCs prior their release by exocytosis at the first 
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synapse. As a consequence of a noxious stimulation, the production and the release of 
vesicles containing endogenous opioid peptides are significantly enhanced.  
Dynorphins have been identified as an important family of endogenous opioid 
peptides with potent analgesic effects. Prodynorphin is the proneuropeptide precursor of 
dynorphins. Early studies have partially described the endoproteolytic processing of 
prodynorphin, including a fundamental role for PC1 and PC2. Those preliminary studies 
established that the action of PC1 and PC2 is needed for the formation of different high 
molecular weight dynorphin-peptides, Bigdynorphin (BDyn), Dynorphin A (Dyn A) and 
Dynorphin B (Dyn B). However, the different contribution of each endoprotease, including 
PC1 and PC2, in the regulation of endogenous BDyn and Dyn A levels still remains unclear.  
The presence of paired and single basic residues on the primary sequence of BDyn 
and Dyn A suggest further C-terminal processing catalyzed by PC1 and PC2 leading to the 
formation of several important N-terminal metabolites. Further processing of BDyn and Dyn 
A can lead to the formation of bioactive peptides including Dynorphin 1-19 (Dyn 1-19), 
Dynorphin A (Dyn A), Dynorphin 1-13 (Dyn 1-3), Dynorphin 1-11 (Dyn 1-11), Dynorphin 
1-10 (Dyn 1-10), Dynorphin 1-7 (Dyn 1-7) and Dynorphin 1-6 (Dyn 1-6). Interestingly all 
these prodynorphin-derived peptides encode a copy of Leu-Enkephalin (Leu-Enk), another 
important opioid peptide, at their N-terminal. Thus, Leu-Enk might be an important 
metabolic product of BDyn and Dyn A. The objective of this project is to study the 
metabolism of BDyn and Dyn A, identify and quantify the rate of formation of the 
metabolites, as well as clarify the role of PC1 and PC2 in regulation of the concentration of 
both neuropeptides.  
This study was designed to develop an in vitro experimental procedure to show the 
enzymatic degradation of BDyn and Dyn A and to elucidate the roles of PC1 and PC2 in the 
proteolytic control of endogenous dynorphins levels. Mice lumbar spinal cord S9 fractions 
were isolated from 3 different mice genotype, wild type (WT), PC1-knockdown (PC1-/+) and 
PC2-knockdown (PC2-/+), and the cellular homogenates containing among other enzymes 
PC1 and PC2, were used as a source of endogenous enzymes for the in vitro digestion. High 
performance liquid chromatography (HPLC) separation coupled with an electrospray 
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ionization mass spectrometer (ESI-MS) was used for the identification and quantification of 
BDyn and Dyn A metabolites. Moreover, an isotopic dilution method was employed for 
peptide quantification.  
The study was designed to provide a better understanding of the mechanisms involved 
in the endogenous control of peptide levels and their impact on pain modulation pathways. 
Since opioid drugs are widely used in pain treatment with serious side-effects, a better 
mechanistic understanding of endogenous opioid metabolic pathways could lead to the 
development of innovative strategies in the treatment of pain. 
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CHAPTER I-ENDOGENOUS MECHANISMS OF PAIN 
 
I.1-Pain generalities 
Pain has been defined by the International Association for the Study of Pain as an 
unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage. This experience is essential for human 
survival since it protects body tissues from damage and alerts of stimulation in any part of 
the body by activating the surveillance mechanism and evoking the so-called muscular reflex 
arc. 
Pain can be caused by diverse methods including physical injuries, infections or other 
forms of noxious stimulation. Understanding the nature of pain as well as its complex 
molecular mechanisms associated with pain perception and transduction is a challenge and 
many of these mechanisms are still not well understood. 
Depending on its nature, pain can be subdivided into neuropathic, nociceptive and 
inflammatory pain. They are each generated for different reasons and need to be treated 
accordingly. 
 
I.2-Pain pathologies 
I.2.1-Neuropathic pain 
The central nervous system (CNS) is responsible for pain perception. Any alteration 
on the CNS can lead to an inadequate perception making pain persist long after the initiating 
cause has ceased (Gold and Gebhart, 2010). Neuropathic pain is provoked from disorders, 
damage or injuries on peripheral nerves, dorsal root ganglion (DRG) or the CNS. Patients 
suffering neuropathic pain exhibit persistent pain independent of a stimulus (Devor, 2006). 
Depending its influence in the sympathetic nervous system, pain perception ranges from a 
persistent burning sensation evoked for any alteration on C-sensory neurons, to acute pain 
perception resulting by large myelinated A fibers. Alterations on the CNS also evoke two 
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characteristic pain sensitizations; hyperalgesia and allodynia (Ossipov and Porreca, 2005). 
Hyperalgesia is characterized as an enhanced and more prolonged pain response to noxious 
stimuli as a result of abnormal processing of nociceptor input. This is a pain hypersensitivity 
that usually accompanies inflammation (Schaible, 2006; Woolf and Salter, 2000). On the 
other hand, allodynia is a state of pain characterized by a pain sensation caused by a normally 
innocuous stimulus. It can be evoked by the action of low threshold myelinated Aβ fibers on 
an altered CNS and by the reduction of the activation threshold of nociceptors present in the 
PNS (Woolf and Mannion, 1999). 
 
I.2.2-Nociceptive pain 
Nociceptive pain, also described as physiological pain, is caused by injuries like cuts, 
burns and other excessive stimulation of nociceptors. Its purpose is to protect tissues from 
further damage activating withdraw reflexes (Schaible, 2006). It is characterized by aching, 
sharp, or throbbing sensations. Well localized, constant and time limited, this kind of pain 
typically resolves once the tissue damage heals (Woolf and Salter, 2000). Treatments with 
opioids-like drugs such as morphine or codeine tends to respond well to nociceptive pain 
(Matthes, et al., 1996; Mogil et al., 1996). 
 
I.2.3-Inflammatory pain 
After injury, primary sensory neurons and other non-neural cells respond producing 
and releasing chemical mediators at the site of tissue injury. This ensemble of chemicals, 
known as inflammatory soup, includes peptides (bradykinins, prostaglandins, interleukins), 
lipids and neurotransmitters (serotonin, ATP) among others chemical compounds. The 
interaction of those compounds with nociceptors leads to an increase of nociceptors 
sensitivity altering neuronal excitability (Julius and Basbaum, 2001). That results in the 
generation of pain in the absence of any stimulation. Moreover, the release of 
neurotransmitters, such as Substance P (SP) and Calcitonin Gene Related Peptide (CGRP), 
from the terminal fibers induces vasodilation and activation of many non-neuronal cells, 
including mast cells and neutrophils, which will contribute to the release of additional 
molecules into the inflammatory soup (Chiu et al., 2012). Inflammatory pain is treated using 
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anti-inflammatory drugs which reduce the release of essential molecules involved in 
neurogenic inflammation (Piomelli et al., 2014; Murata et al., 1997). 
 
I.3-Pain physiology  
I.3.1-Nociceptive process 
The nociception process includes the detection of noxious stimuli at cutaneous and 
deep somatic tissues innervated by primary afferent neurons, and the subsequent transmission 
of that information to the brain. The afferent neurons present nociceptors on their terminals 
that are responsible for noxious or damaging stimuli transduction being activated when the 
stimuli are sufficient to initiate an action potential (Kidd and Urban, 2001). The information 
encoded as an action potential is then transmitted through afferent neurons located in the 
dorsal horn of the spinal cord where, within specific laminae, a synaptic transmission will 
occur with second order neurons. Sensory information is then carried through these 
secondary order neurons to supraspinal structures where it is transduced and finally perceived 
as pain. (Woolf and Salter, 2000). 
 
I.3.1.1-Primary sensory neurons 
Nociceptors are commonly associated with primary afferent neurons (Aδ and C 
fibers) relaying information about noxious perceptions from the periphery to the CNS, 
making up the so-called nociceptive system. Primary sensory neurons are activated when a 
harmful or damaging stimuli are perceived by the nociceptors. C-fibers and Aδ-fibers are 
considered as the afferent fibers signaling nociceptive perceptions whereas Aβ-fibers are not 
involved on pain transmission and they predominantly carry information concerning 
innocuous perceptions such light touch or pressure (Figure 2). 
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Figure 1: Primary afferent neurons include large-diameter (Aβ), medium-diameter (Aδ) and small-
diameter unmyelinated (C) afferent fibers (Adapted from Julius and Basbaum, 2001) 
 
Aβ fibers have the largest diameter and are myelinated. The layer of myelin, a 
dielectric compound which prevents the electric current from leaving the axon, confers a high 
speed of propagation of impulses along these fibers (Russell, 1992). Aβ fibers are not 
involved in pain perception but allow the integration of innocuous stimuli such as cold or 
warm feeling, sense of touch, vibration and light pressure (Julius and Basbaum, 2001). 
Aδ fibers are medium-diameter fibers and are also myelinated. They are polymodal 
and more importantly, play a central role in the transmission of intense heat, mechanical and 
chemical noxious perception. The high speed of propagation of noxious stimuli though these 
fibers, conferred by their myelination and diameter, link Aδ fibers on the perception of acute 
and fast pain called first pain (Adriaensen et al., 1983). 
C-fibers, are the smallest in diameter and are unmyelinated. Their small diameter and 
the lack of myelination results in a slow conduction velocity (Bouhassira, 2009). These fibers 
mediate the so-called second or slow pain. C-fibers are also polymodal responding to thermal, 
mechanical and chemical stimuli (Basbaum et al., 2009). Both Aδ and C-fibers have elevated 
activation threshold and are involved in noxious stimulus perceptions (Schaible, 2006). 
 
I.3.1.2-Ion channels  
Harmful or damaging stimuli perception is mediated in the first instance by voltage-
gated ion channels composed of complex transmembrane proteins. The activation of ion 
channels leads the efflux or influx of specific ions through the channel resulting in a 
polarization or depolarization of the cell membrane modulating the electrical excitability of 
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neurons. A vast majority of nociceptors are ion channels or are associated with them allowing 
rapid membrane depolarization (Takayama et al., 2015). Ion channels permeable to different 
ions have been identified along the CNS. They play a fundamental role in the generation of 
action potentials and their propagation through afferent fibers. 
I.3.1.2.1-Sodium channels 
Voltage-gated sodium channels (Nav) are present in all sensory neurons. They initiate 
action potentials in neuronal cells though the influx of Na+, producing a fast depolarization 
of the membrane. Many Nav have been identified and they have similar functions (Goldin et 
al., 2000). Nav1.7, Nav1.8 and Nav1.9 have been demonstrated to be critical for pain 
perception. Genetically engineered mice lacking those channels shown a clear insensibility 
to pain (Cummins et al., 2007).  
I.3.1.2.2-Calcium channels 
In neuronal cells, calcium voltage-gated channels (Cav) are the principal ionic 
channels involved in regulating the release of neurotransmitters during synaptic transmission. 
Cav2.2, located on nerve terminals, has been described to be essential for initiating 
presynaptic neurotransmitter release by neuronal cells as a response to the influx of Ca2+ 
(Catterall, 2000; Catterall and Few, 2008). Moreover, the influx of Ca2+ through Cav into cell 
cytosol is also crucial to regulate the activity of cytosolic enzymes and other biochemical 
processes (Flavell and Greenberg, 2008). In addition, as shown below, several nociceptors, 
such as TRPV receptors are in fact Cav, the activation of which leads to membrane 
depolarization and the generation of action potentials (Fernández-Carvajal et al., 2011). 
I.3.1.2.3-Potassium channels 
Potassium channels are primarily involved in repolarizing the membrane. The influx 
of K+ though these channels modulates the formation of action potentials on sensory neurons. 
The activity of potassium channels is essential to control the length and frequency of the 
action potential (Brady et al., 2005). In addition, potassium channels have been demonstrated 
to be associated with various opioid receptors, which open specific potassium channels and 
prevent the excitation and propagation of action potentials (Ocaña et al., 2004). 
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I.3.1.2.4-Chloride channels 
The concentration of Cl- ions in neurons is low, therefore an influx or efflux of Cl- 
through chloride channels drastically leads to a rapid membrane polarization or 
depolarization respectively, making these channels crucial for the control of neuronal 
excitability (De Koninck, 2007). Chloride channels such as anoctamin 1 have been found 
associated with nociceptors providing a rapid depolarization mediated by the efflux of Cl- 
(Takayama et al., 2015). In contrast, the activation of the chloride channels γ-aminobutyric 
acid (GABA) receptors, one of the most important synaptic receptors, leads to a 
hyperpolarization of the membrane by the influx of Cl-, resulting in a reduction in the 
probability of action potential initiation and causing neuronal inhibition (Brady et al., 2005; 
Duran et al., 2010).  
 
I.3.1.3-Pain receptors, nociceptors 
Pain usually starts with the activation of sensory receptors known as nociceptors 
(Woolf, 2011; Scholz and Woolf, 2002). Nociceptors are located at terminal axons of 
peripheral sensory neurons that innervate skin, organs, joints and viscera. Nociceptors are 
able to respond selectively to different tissue stimulations (Gold and Gebhart, 2010). They 
respond to specific noxious threshold stimuli but do not respond to innocuous stimuli. Their 
activation can result from noxious heat and cold perception (heat/cold sensitive receptors), 
from chemical compounds (sensitive to chemical compounds receptors) or from mechanical 
stimuli (mechano-transducers) (Figure 1) (Schaible, 2006). The activation threshold of those 
different nociceptors depends on the tissue or organ innervated. As an example, activation 
threshold in tissues such as the cornea is low compared to other tissues such as the skin (Gold 
and Gebhart, 2010). Moreover, the sensitivity of nociceptors can be altered after tissue injury 
owing to the release of inflammatory chemical compounds which reduce nociceptor 
activation threshold (Chiu et al., 2012). The excitation of nociceptors by mechanical, thermal 
and chemical stimuli evokes membrane depolarization, leading to the generation of an action 
potential. (Gold and Gebhart, 2010) 
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Figure 2: Thermal, mechanical and chemical noxious stimuli are perceived by nociceptors located 
at the terminal of afferent neurons. The activation of nociceptors leads to the generation of action 
potentials which rely noxious perceptions to the brain (Adapted from Scholz and Woolf, 2002). 
 
I.3.1.3.1-Heat sensitive receptors 
Transient receptor potential vanilloids (TRPV) are responsible for heat stimuli 
perception. Their thermal stimulation open the channels and allow the influx of Ca2+, 
resulting in cell depolarization (Schaible, 2006). Heat-sensitive TRPV receptor family 
comprises 3 essential receptors TRPV1, TRPV2 and TRPV3.  TRPV1 and TRPV2 are 
activated by noxious heat (>42° C) (Fernández-Carvajal et al., 2011), whereas TRPV3 is 
activated by innocuous warmth (30°C–40°C), maintaining its activation at noxious 
temperatures. Those receptors and expressed at high levels along the PNS and CNS in small 
diameter C and Aδ fibers. Its activity is enhanced under inflammatory pain conditions (Julius 
and Basbaum, 2001).  
I.3.1.3.2-Chemical sensitive receptors 
Acid-sensing ion channel receptors (ASICs) are the most important and studied 
chemical sensitive receptor. ASICs are Na+ channels opening at acidic pH (<5) (Sazanavets 
and Warwicker, 2015; Babinski et al., 1999). They serve among other things as a receptor 
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for extracellular proton release following a tissue injury (Sutherland et al., 2001). In addition, 
some thermo-sensitive nociceptors such as TRPV1 and TRPM8 are also considered 
chemically sensitive receptors. TRPM8 can be activated, in addition to thermal stimulus, by 
menthol and TRPV1 by capsaicin and acids (Karashima et al., 2007; Bandell et al. 2004). 
The importance of the polyvalence of some nociceptors is reflected, for example, by the 
involvement of TRPV1 receptors on the burning pain perceived during inflammation, which 
is a result of the interaction of protons contained in the inflammatory soup with TRPV1 heat-
sensitive receptors (Reid and Flonta, 2001). Chemical sensitive receptors have been reported 
to be present along PNS and CNS in C and Aδ fibers (Iida et al., 2003). 
I.3.1.3.3-Mechano-transducers 
Although the molecular mechanisms of mechano-transducers are not fully 
understood, recent studies suggested a major role for degenerin/epithelial Na+ channel 
(DEG/ENaC) and K+ channel subfamily K (KCNK) for the transduction of mechanical 
stimulus (Mano and Driscoll, 1999; Bautista et al., 2008). Likewise, the TRPV2 channels can 
respond to osmotic stretch in addition to noxious heat, denoting their role in mechano-
transduction (Basbaum, et al., 2009). A variety mechano-transducer ranging from high 
threshold activation mechano-receptors are found on C and Aδ fibers and low threshold 
mechano-transducers which are found on Aβ fibers capable of detecting light pressure, 
vibration or texture.  
I.3.1.3.4-Cold sensitive receptors 
Transient receptor potential melastatin 8 (TRPM8) and transient receptor potential 
ankyrin 1 (TRPA1) ion channels have been proposed as the most essential cold sensitive 
receptors, whose activation allows the entry of Na+ and Ca2+ ions to the cell. TRPM8 is the 
best known cold sensitive receptor. This receptor is responsible for cold perceptions within 
the range of innocuous temperatures below 30°C. (Fernández-Carvajal et al., 2010). On the 
other hand, TRPA1 receptor is responsible for the perception of cold stimuli within noxious 
range (<15ºC) (Basbaum, et al., 2009). Both TRPM8 and TRPA1 are also sensitive cooling 
agents such as menthol and eucalyptol (Karashima et al., 2007; Bandell et al. 2004). These 
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nociceptors were identified on C and Aδ fibers, into the CNS and in a variety of tissues 
(Dhaka et al. 2007; Simone and Kajander 1996). 
 
I.3.2-Ascending pathway 
Sensory information perceived by the nociceptors is carried through the primary 
afferent neurons and reach the spinal cord. The ascending pathway comprises the process of 
signaling between primary afferent neurons and secondary order neurons at the spinal cord, 
as well as the ascension of the information through the secondary order neurons to 
supraspinal structures (Figure 3). In the brain noxious information is translated and then 
perceived as a noxious stimuli. The signaling process between primary afferent neurons and 
secondary order neurons is known as the first synapse. This process takes place at the spinal 
cord and allows the communication between neurons via the release of neurotransmitters. 
 
Figure 3: Schematic of the pain pathway. (1) The PNS is responsible of noxious stimuli perception 
and the transmission of noxious information to the spinal cord though primary afferent neurons. (2) 
Signaling between afferent and secondary neurons take place at the first synapse. (3) These 
secondary order neurons transmit the information to the thalamus which engage the somatosensory 
cortex, providing information about the location and intensity of the painful stimulus. Other 
projections engage the thalamus with cingulate cortex and amygdala, contributing to the emotive 
component of the pain experience. (4) Noxious stimulus inputs  activates the endogenous 
modulating system, stimulating the synthesis of endogenous opioids and their release into the first 
synapse, resulting in a modulation of the synaptic activity (Adapted from de Lalouvière et al. 2014). 
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I-3.2.1-First Synapse 
In the late 19th century the first neuronal connections were discovered. The 
connections were found to be discontinuous and the communication between neurons was 
observed to be carried out by the so-called synaptic transmission (López-Muñoz et al., 2006). 
Nowadays the communication between neurons is known to be mediated by the release of 
excitatory neurotransmitters from the terminal of primary neurons. Through the interaction 
of these released neurotransmitters with their receptors located on secondary neurons, the 
secondary neurons are activated and the information is transferred. The first synapse is the 
process through which the PNS and the CNS are connected. It takes place at the dorsal horn 
of the spinal cord within laminae I to V and allows the signaling between afferent and 
secondary order neurons which relay information to supra-spinal structures (Basbaum et al., 
2009).  
The synaptic process is a dynamic mechanism of neurotransmitters release which 
keeps a basal activity of sensory neurons. However, noxious stimulations of the PNS and 
CNS enhances the activity at the first synapse. Action potentials generated as a consequence 
of a harmful perception by the nociceptors, are propagated through primary sensory neurons 
stimulating the synthesis of specific peptidergic neurotransmitters at the DRG along with the 
opening the Ca2+ channels at the terminal of the neuron. These peptides involved in the 
signaling of noxious information between neurons are packed into secretory vesicles and are 
carried through the axons to the presynaptic terminal (Zhang et al., 1995). The high 
concentrations of Ca2+ at the terminal, caused by the Ca2+ influx through the Ca2+ channels 
activated by the action potential, facilitate the release of the vesicle content from the 
presynaptic terminal into the synaptic gap by exocytosis (Margeta et al., 2008; Südhof, 2004). 
The interaction between the released neurotransmitters with specific post-synaptic receptors 
stimulates the postsynaptic terminal and generates a new action potential at the secondary 
order neuron (Brady et al., 2005). 
 
 
15 
 
 
 
I-3.2.1.1-Principal synaptic neurotransmitters and receptors 
Several neurotransmitters are involved in the neuronal synaptic communication. 
Glutamate and ϒ-aminobutyric acid (GABA) are the major chemical neurotransmitters 
involved, and it is believed that approximately 80-90% of the synapses in the CNS are 
glutamatergic (Brady et al, 2005). Glutamine is synthesized in neurons and metabolized to 
glutamate by the mitochondrial enzyme glutaminase (Olsen and DeLorey, 1999). Glutamate 
binds to N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA) postsynaptic receptors producing excitatory postsynaptic response 
(Purves et al., 2001). The NMDA receptor is an ionotropic receptor which, following 
activation, produces an influx of cations mainly Na+ and K+ but also Ca2+ into the cell. On 
the other hand, AMPA receptor is also an ionotropic transmembrane receptor, and which 
gates mainly Na+ and K+, but not Ca+2 ions. Their activation and the consequent influx of 
cations produces a membrane depolarization at the postsynaptic terminal, resulting in the 
generation of an action potential (Purves et al., 2001). Glutamate is the precursor for GABA, 
a major inhibitory neurotransmitter. GABA activates GABA receptors, which are ionotropic 
channels permeable to Cl-. The transmembrane influx of Cl- through GABA receptors leads 
to membrane hyperpolarization reducing the presynaptic release of neurotransmitters as well 
as the excitability of postsynaptic receptors (Petroff et al., 2002; Schousboe et al., 2007).  
The perception of intense stimulus is directly associated with the release of 
peptidergic excitatory neurotransmitters including tachykinins and calcitonin gene-related 
peptide (CGRP). Thus, perceptions on the noxious range promote the production of 
tachykinins and CGRP at the DRG and their subsequent release into the synaptic gap. 
Tachykinins are a family of neurotransmitters that includes peptides such as Substance P 
(SP), Neurokinin A (NKA) and Neurokinin B (NKB). These tachykinin-related peptides act 
on neurokinin receptors (i.e. NK1, NK2 and NK3). The activation of neurokinin receptors, 
particularly the activation of NK1 by SP, generates a greater post-synaptic response and 
enhances NMDA receptors activity (Gao and Peet, 1999; Teodoro et al., 2013). CGRP also 
plays an important role in nociception, it is a potent vasodilator and the release of CGRP 
potentiates the action of SP by inhibiting its enzymatic degradation and by enhancing its 
release (Gangula et al., 2000; Bennett et al., 2000; Biella et al., 1991). 
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I.3.3-Descending pathway 
The perception of well-being is the result of the equilibrium between an incessant 
release of excitatory neurotransmitters at spinal levels, which allow the brain to perceive 
noxious information, and the suppressive influences of the same importance that descends 
from the brain. When the ascending signal is more intense than the suppressing action, pain 
appears (Beaulieu 2005).  
By the time the brain receives noxious stimuli inputs this perception is projected to 
the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM) activating the 
descending pathway (see Figure 3) and leading to a nociceptive modulation (Lovick, 1991; 
Helmstetter et al., 1998). This modulating process is principally mediated by the release of 
endogenous opioid peptides from descending interneurons into the first synapse. Through the 
interaction of these opioid peptides with their respective pre- and post-synaptic opioid 
receptors the synaptic activity is modulated, reducing the intensity of noxious perceptions.  
 
I.3.3.1-Opioid receptors and endogenous opioid peptides  
Since their discovery in 1970s, research related to opioid peptides revealed 
fundamental CNS functions (Brownstein, 1993). Endogenous opioid peptides participate in 
pain modulation producing analgesia and a sense of well-being (Froehlich, 1997). 
Synthetized as large and biologically inactive precursors at the DRG, pituitary and adrenal 
gland, they require enzymatic processing to generate active opioid peptides. Similar to other 
neuropeptides, opioid peptides are synthetized and packed into dense core vesicles (Hook, 
2006). Following noxious stimuli, the synthesis and release of these vesicles are enhanced, 
leading to measurable modulatory effects on pain perception (Alberts et al., 2002). 
 Opioid peptides are classified into four major families; endorphins, endomorphins, 
enkephalins and dynorphins. Each family is derived from a distinct precursor (Figure 4) and 
has a characteristic anatomical distribution and physiological activities (McDonald and 
Lambert, 2014). Moreover, each family of endogenous opioid peptides has specific affinity 
for the opioid receptors present into the CNS. These receptors include µ-opioid receptors 
(MOR), κ-opioid receptors (KOR) and δ-opioid receptors (DOR) (Table 1). 
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Precursor Endogenous peptide Amino acid  sequence 
Affinity for Opioid 
receptors 
MOR DOR KOR 
Pro-
Opiomelanocortin β-endorphin 
YGGFTMTSEKSQTPLVYLFKNAIIKN
AYKKGE +++ ++ - 
Unknown 
Endomorphin-1 YPWF-NH2 +++ - - 
Endomorphin-2 YPFF-NH2 +++ - - 
Pro-Enkephalin 
Met-Enkephalin YGGFM ++ +++ - 
Leu-Enkephalin YGGFL + +++ - 
Pro-Dynorphin 
Dynorphin A YGGFLRRIRPKLK + - +++ 
Dynorphin B YGGFLRRQFKVVT + + +++ 
 
Table 1: Most representative opioid peptide derived from the processing of their respective 
precursors. Affinity observed for opioid receptors (Stein et al. 2009; Merg et al., 2006; Beaulieu, 
2005; Mansour et al., 1995; Raynor et al., 1994). 
 
I.3.3.1.1-Opioid receptors  
Opioid receptors are G protein-coupled receptors characterized by 7 transmembrane 
domains. Pharmacological, behavioral, and receptor binding studies have suggested the 
existence of at least three types of opioid receptors including MOR, KOR and DOR (Snyder 
and Pasternak, 2003). These receptors are highly abundant in the brain and the spinal cord. 
Opioid receptors are mainly located in the superﬁcial dorsal horn (Zöllner and Stein, 2007). 
These receptors induce specific pharmacological response and they differ in their binding 
characteristics, even though a specific opioid peptide can interact with more than one type of 
opioid receptor (Lutz and Pfister, 1992; Ji et al., 1995; Mcnally and Akil, 2002).  
The binding of opioid peptides to opioid receptors initiates a series of biochemical 
events that usually culminates in the stimulation of potassium efflux though the potassium 
ion channels, leading to a repolarization that results in various effects, including analgesia 
and euphoria (Ikeda et al., 2002; Maldonado et al., 2001; North et al., 1987). KORs are 
located presynaptically on primary afferent neurons in the dorsal horn of the spinal cord 
where they participate in the inhibition of the release of excitatory neurotransmitters such as 
SP, CGRP and glutamate. DORs are present on postsynaptic terminals of secondary order 
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neurons, and they decrease the excitability provoked by the activation of other postsynaptic 
receptors such as NK1 and NMDA. MORs are located either at presynaptic or postsynaptic 
terminals, therefore, MORs can either modulate the release of excitatory neurotransmitters 
or decrease the excitability of postsynaptic receptors (McDonald and Lambert, 2014).  
I.3.3.1.2-Endorphins 
Endorphins are endogenous opioid peptides produced during arduous exercise, 
excitement or pain perception, specifically inducing analgesia and well-being feeling 
(Sprouse-Blum et al., 2010). They are found widely distributed in the PNS and CNS 
(Marvizón et al., 2009). Endorphins are derived from the precursor proopiomelanocortin 
(POMC) a 241 amino acids protein (Smith et al., 1988). Its endoproteolytic processing by 
protein convertases (PCs) generate various bioactive peptides, such as β-endorphin (β-End), 
in addition to several non-opioid neuropeptides including adrenocorticotropic hormone 
(ACTH) and α-, β-  and γ- melanocyte-stimulating hormone (α-MSH, β-MSH and γ-MSH) 
(Mousa et al., 2004). Binding affinity experiments of β-End for opioid receptor have shown 
a primary affinity for MOR, even though a high affinity for DOR was also reported (Mansour 
et al., 1995). 
 
Figure 4: Opioid-derived peptides are generated from the endoproteolytic processing of proopioid 
precursors POMC, PDyn and PEnk. With the exception of dynorphins, the enzymatic formation of 
opioids peptide are regulated by cleavages at dibasic amino acid positions.   
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I.3.3.1.3-Enkephalins 
Enkephalins are pentapeptides found in many different regions in the CNS, 
suggesting that these peptides are involved in many physiological functions.  Among other 
functions enkephalins are involved in pain perception, mood and behavior by altering 
emotional responses as well as by acting on cardiovascular and respiratory functions 
(Przewłocki and Przewłocka, 2001; Mediavilla, 1977). In pain modulation, enkephalins have 
a potent action but with a short duration due to their rapid degradation by metallopeptidases 
(Mosnaim et al., 2008). Proenkephalin (PEnk), a protein constituted of 267 amino acids, is 
proteolytically cleaved into enkephalin peptides. PEnk processing by PCs results in the 
generation of 4 copies of Met-enkephalin (Met-Enk) and one copy of Leu-Enkephalin (Leu-
Enk) (Loh et al., 2002). Both enkephalins have high affinity for DOR and moderate affinity, 
approximately tenfold lower, for MOR (Roques et al., 2012; Zöllner and Stein, 2007). 
I.3.3.1.4-Endomorphins  
The most recent family of endogenous opioid peptides discovered is endomorphins. 
They have a key role in pain perception, responses related to stress, and complex functions 
such as reward, arousal, and vigilance (Fichna et al., 2007). Although the endomorphin 
precursor still remains unidentified, two endomorphin peptides have been identified; 
endomorphin-1 (EM-1) and endomorphin-2 (EM-2). Both endomorphins differ just in one 
amino acid and are quite distinct from the other opioid peptides (endorphins, enkephalins and 
dynorphins), which all share the YGGF amino acid sequence at the N-terminus. EM-1 and 
EM-2 are widely distributed throughout the CNS and bind selectively to the MOR. Both 
endomorphin peptides have high affinity and similar potency for MOR (Zadina et al., 1997; 
Hackler et al., 1997; Martin‐Schild et al., 1999).  
I.3.3.1.5-Dynorphins  
Endogenous dynorphin peptides are generated from the endoproteolytic processing of their 
precursor prodynorphin by PCs. This family of dynorphin peptides includes big dynorphin, 
dynorphin A and dynorphin B. They have primary affinity for KOR and their biological 
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functions comprise, among several others, a key role in pain modulation. The functions of 
the principal dynorphin peptides will be thoroughly described in the next chapter. 
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CHAPTER II-DYNORPHINS 
II.1-Dynorphins generalities 
The modulation of sensory information has been shown to take place in the dorsal 
horn of the spinal cord, more specifically at the first synapse (Honore et al., 2000; Levine, 
1993). Dynorphins are a family of endogenous opioid peptides that have potent analgesic 
effects and have been identified as neuropeptides involved in endogenous pain inhibition 
(Kuner, 2010; Mika et al., 2011). Dynorphin peptides are widely distributed in the 
mammalian CNS and have a primary affinity for KOR (Stein et al. 2009; Schaible, 2006). 
This class of opioid peptides is known to be involved in a wide range of functions, including 
mood, motor activity and homeostatic response to injury and contributes to perceptual 
distortion in schizophrenia, dementia and bipolar disorders. An altered expression of 
dynorphins is also observed in drug abusers and psychiatric patients (Solbrig and Koob, 
2004; Hurd, 2001; Hurd et al., 1996). Like other endogenous opioid peptides, bioactive 
dynorphins result from the processing of its large and inactive precursor, Prodynorphin 
(PDyn). PCs, specifically PC1 and PC2, found in neuronal and endocrine cells, were reported 
to be involved into PDyn proteolytic processing by cleaving its basic amino acid residues 
(Berman et al., 2000; Dupuy et al., 1994; Day et al., 1998).  
 
II.2- Prodynorphin 
Dynorphin peptides are derived from PDyn, a 254 amino acid biologically inactive 
protein which undergoes enzymatic degradation by PCs generating dynorphin peptides. 
PDyn was first characterized in 1982 from porcine neuronal tissues by using cDNA 
hybridization (Kakidani et al., 1982). As shown in figure 5, mouse, rat and human PDyn 
present a high homology at the amino acid level, sharing an identical sequence for the region 
encoding dynorphin A (Dyn A) and dynorphin B (Dyn B) (Civelli et al., 1985).  
PDyn, similarly to other proneuropeptides, is synthesized in the endoplasmic 
reticulum (ER), of neuronal cells, and is transferred to the Golgi apparatus where it is packed 
in dense core vesicles together with the endoproteases PC1 and PC2 (Hook et al., 2008). 
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Dense core vesicles are then transported along the axons to the nerve terminal. Classical 
models postulated that PDyn processing by endoproteases starts at the trans-Golgi network 
(TGN) and continues during the axonal transport of the secretory vesicles (Hökfelt et al., 
2000; Alberts et al., 2002). Potassium-induced depolarization produced by neuronal activity, 
stimulates the production, the migration and the exocytotic release of dynorphin-containing 
vesicles into the first synapse (Seidah and Chrétien, 1999; Zhou et al., 1999; Arvan and 
Castle, 1998). Others have proposed that vesicles containing unprocessed PDyn are stored at 
the nerve terminal waiting for depolarization to induce precursor processing and its release 
into the synaptic space (Yakovleva et al., 2006). 
The highest concentrations of unprocessed PDyn are found in the hypothalamus, 
striatum, and hippocampus. Less important amounts are also found in the midbrain, nucleus 
tractus, brainstem, and cerebral cortex. In non-brain tissues, PDyn is found in the adrenal 
gland, spinal cord, testis, and anterior pituitary (Civelli et al., 1985).  
 
 
Figure 5: Mouse, rat and human Prodynorphin proteomic alignment. High homology is observed in 
multiple regions between species. The region encoding BDyn is completely homologue for the three 
species. This homology shows high conservation of this gene through evolution. 
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II.3-Endogenous Dynorphin peptides 
Several active dynorphin peptides have been identified in mammalian brain and 
spinal cord as potential products from PDyn proteolytic processing. These PDyn-derived 
peptides include BDyn, Dyn 1-19, Dyn A, Dyn B, Dyn 1-13, Dyn 1-11, Dyn 1-10, Dyn 1-9, 
Dyn 1-8, Dyn 1-7 and Dyn 1-6 (Lu et al., 2001; Mansour et al., 1995; Reed et al., 2003; 
Prokai et al., 1998; Chou et al., 1994) (Table 2). So far, BDyn, Dyn A and Dyn B have been 
the dynorphin peptides which were extensively studied with a strong emphasis on Dyn A 
physiological activities.  
 
Peptide Amino acids Sequence 
Bigdynorphin 1-32 YGGFLRRIRPKLKWDNQKRYGGFLRRDFKVVT 
Dynorphin 1-19 1-19 YGGFLRRIRPKLKWDNQKR 
Dynorphin A 1-17 YGGFLRRIRPKLKWDNQ 
Dynorphin B 20-32 YGGFLRRDFKVVT 
Dynorphin 1-13 1-13 YGGFLRRIRPKLK 
Dynorphin  1-11 1-11 YGGFLRRIRPK 
Dynorphin 1-10 1-10 YGGFLRRIRP 
Dynorphin 1-9 1-9 YGGFLRRIR 
Dynorphin 1-8 1-8 YGGFLRRI 
Dynorphin 1-7 1-7 YGGFLRR 
Dynorphin 1-6 1-6 YGGFLR 
 
Table 2: Prodynorphin-derived peptides amino acid sequences   
 
Dyn 1-19, in spite of being the major product from Bigdyn endoproteolytic 
processing (Berman et al., 2000), owing to its rapid conversion into Dyn A by 
carboxipeptidases is not a highly abundant peptide in the CNS and its role is still quite unclear 
(Berman et al. 2001). 
Dyn 1-13 has been presented as an extraordinarily potent opioid peptide with a long 
duration of action (Goldstein et al., 1979), acting on KOR (Oka et al., 1982). Its 
administration was reported to induce catalepsy and analgesia in rats (Herman et al., 1980). 
Studies also shown that the expression of opiate withdrawal symptoms after the 
administration of Dyn 1-13 were suppressed in mice (Takemori et al., 1992 and 1993; Khazan 
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et al., 1983; Aceto et al., 1982; Hooke et al., 1995), suggesting that, in vivo, Dyn 1-13 does 
not behave as a typical KOR agonist, but its role still needs to be clarified.    
On the other hand, the effects of Dyn 1-11, Dyn 1-10, Dyn 1-9, Dyn 1-8, Dyn 1-7 and 
Dyn 1-6 remains relatively unexplored. Even though they have been identified as proteolytic 
products of PDyn, BDyn or Dyn A, just few studies have been published corroborating their 
antinociceptive effects, while their specific physiological role still remains to be determined 
(Lu et al., 2001; Mansour et al., 1995; Reed et al., 2003; Prokai et al., 1998; Chou et al., 1994; 
Herman et al., 1980). 
 
II.3.1-BigDynorphin 
BDyn is the largest and bioactive PDyn-derived peptide, consisting on Dyn A and 
Dyn B bound by arginine-lysine (KR) paired basic amino acids. In addition to serving as a 
precursor for Dyn A and Dyn B, this peptide may also have its own function. Found at 
substantial levels in the pituitary gland, brain and spinal cord (Xie and Goldstein, 1987; Day 
and Akil, 1989), the effects of BDyn differs from those of the other dynorphin peptides. The 
intrathecal and intracerebral administration of BDyn to mice were reported to produce a 
nociceptive behavioral response of the animal (Tan-No et al. 2002). These nociceptive 
responses were associated with the interaction of BDyn with NMDA receptors (Merg et al., 
2006; Chen et al., 1995). In addition, the binding affinities and potency of BDyn for opioid 
receptors were also studied, showing that BDyn also has a strong affinity for KOR. Although 
BDyn affinity for KOR was comparable to Dyn A, its potency was significantly greater 
compared to other dynorphins such as Dyn A or Dyn B (Merg et al., 2006; Kuzmin et al., 
2006). 
The selectivity and potency of BDyn in activating KOR along with the behavioral 
effects observed in mice, mediated by the activation of NMDA receptors, suggest that a 
deficient processing of PDyn, resulting in high levels of BDyn, could lead to an enhancement 
on nociceptive perception, while a normal processing of PDyn leads generally to a 
predominant activation of KOR by BDyn and other dynorphin peptides, resulting in 
antinociceptive effects. 
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II.3.2-Dynorphin A 
Dyn A was the first dynorphin peptide to be identified (Cox et al., 1975). The 
observation of potent analgesic effects when administered intrathecally to mice raised the 
interest in this opioid peptide for further studies in pain research (Hayes et al., 1983). Dyn A 
is widely found throughout the CNS, being more abundant especially in the brain, in areas 
like hypothalamus, substantia nigra and periaqueductal gray. High concentrations are also 
found in the dorsal horn of the spinal cord and in the pituitary gland. (Tan-No et al., 1997).  
Studies revealed that Dyn A participates in pain modulation pathways, mediated in 
part by its release in the brain and spinal cord (Mizoguchi et al., 2006). Its participation in 
the first synapse was corroborated a posteriori when high levels of Dyn A were found in 
intrinsic neurons projecting into laminae I, II and V of the spinal cord dorsal horn (Draisci et 
al., 1991; Przewlocki et al., 1983), where neurons responding to noxious input are contained 
(Mika et al., 2011). Subsequent studies based on the injection of Dyn A into the subarachnoid 
space of the spinal cord of rats showed a strong and long-lasting analgesic effect, with a 
greater potency than morphine (Merg et al., 2006). That effect was completely reversed by 
the administration of naxolone, a potent opioid receptor antagonist, demonstrating that Dyn 
A acts on KOR (Han and Xie, 1982; Nakazawa et al., 1985). The affinity and potency of Dyn 
A for KOR has been reported to be substantially higher than for other dynorphin peptides 
(Merg et al. 2006). However, intrathecal administration of Dyn A at high doses was observed 
to induce long-lasting mechanical and thermal allodynia in rats, a response that was not 
blocked by naloxone, suggesting that when Dyn A is administered at high doses, it is able to 
interact with other receptors such as NMDA in addition to KOR (Laughlin et al. 1997; 
Vandera et al. 1996; Shukla et al. 1994). Those studies suggested that Dyn A has inhibitory 
or excitatory effects, depending on its concentration (Caudle et al. 1994).  
II.3.2.1-Physiological role of Dynorphin A 
EM-2 has been proposed to have an important involvement in antinociception 
mediated by Dyn A at spinal cord levels (Draisci et al., 1991). The mechanism proposed by 
Mizoguchi and co-workers (Mizoguchi et al. 2006) and later supported by Fichna and co-
workers (Fichna et al. 2007) establish that the release of Dyn A from descending interneurons 
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and its subsequent interaction with presynaptic KOR, promote the production and release of 
EM-2 from the terminal of primary afferent neurons. The released EM-2 preferentially 
stimulates MOR, a presynaptic and postsynaptic receptor, leading to the inhibition of the 
release of excitatory neurotransmitters such as SP, glutamate and CRGP, as well as causing 
a decrease of the excitability of postsynaptic receptors such as NMDA or NK1 receptors 
(Figure 5). Moreover the presence of MOR in the descending dynorphin-containing neurons 
also make EM-2 having an important regulator of the release of Dyn A (Ohsawa et al., 2001; 
Sakurada et al., 2001; Mizoguchi et al., 2006; Fichna et al., 2007).  
 
 
Figure 6: Involvement of Dyn A in pain modulation. (1) The release of Dyn A enhances the 
production and release of EM-2. Thus through its interaction with MOR, EM-2 (2) inhibits the 
release of excitatory neurotransmitters and (3) decreases the excitability of postsynaptic receptors 
in addition to (4) regulate the release of Dyn A. (Fichna et al., 2007) 
 
II.3.3-Dynorphin B 
As a primary product from Bigdyn, Dyn B is present in the same neuronal fibers and 
tissues that contains Dyn A (Zamir, 1984). Dyn B has a primary affinity for KOR, however 
its affinity for the receptor and its potency is lower compared to Dyn A (Merg et al., 2006). 
Intrathecal injections of Dyn B in rats produced potent and long-lasting analgesic effects 
(Han and Xie, 1982). Nevertheless, the physiological role of Dyn B is still far from clear. 
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Mizoguchi and colleges reported that the physiological role of Dyn B completely differs from 
Dyn A. They observed that Dyn B activated KOR induced the release of another potent 
antinociceptive peptide, analogue to dermorphin (Mizoguchi et al. 2006a). This mechanism 
of action was similar to the role observed for Dyn A involving the release of EM-2. These 
interesting findings strongly suggest that the dynorphin peptides act through separate 
pathway to bring about pain relief. 
II.4-Proprotein convertases 
Several neuropeptides and hormones as well as a variety of other endogenous 
peptides are derived from large and inactive proteins which require endoproteolytic 
processing for the biosynthesis of the active peptides. Protein convertases (PCs) are a family 
of enzymes catalyzing protein cleavage at monobasic amino acid residues such as single 
lysine (K) or arginine (R) as well as at paired basic residues such as RR, KR, RK and KK 
(Hook and Brennand, 2014; Rouillé et al., 1995). As an exception, when a basic position is 
flanked by a proline at the C-terminal, the conformational restrictions imposed by this amino 
acid on the peptide avoids any possible cleavage by PCs (Vanhoof et al. 1995). 
Seven PCs were identified in mammalian tissues including PC1, PC2, PC4, PC5 , 
PACE4, PC7 and  furin, officially named as proprotein convertase subtilisin/kexin type 1, 2, 
4, 5, 6,7 and furin respectively (Seidah et al. 1998). Like most secreted proteins, PCs are 
synthesized in the ER as immature PCs which require post-translational modifications to 
become fully active (Seidah et al. 2008). Following their synthesis, PCs are transported 
to downstream compartments of the secretory pathway where they are N-glycosylated at 
various sites and folded into an active conformation within the ER (Benjannet et al. 1993; 
Steiner, 1998). As an exception, PC2 does not follow this process, instead, immature PC2 
is transported with a binding protein (7B2) to acidic immature secretory granules, where it is 
autocatalytically activated (Mousa et al., 2004; Mbikay et al., 2001).  
PCs and other secreted proproteins are then packed in secretory vesicles as they 
leave the ER. During the transport of those vesicles, active PCs process proproteins within 
the vesicles (Alberts et al., 2002). PCs require Ca2+ as a cofactor to cleave their substrates 
(Linard et al., 1995). In addition, PC1 and PC2 are maximally active in the acidic pH 
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environment (5.5-6.5) of immature secretory granules (Shennan, 1995), being less effective 
outside the vesicles (Seidah and Prat, 2012). Since all PCs possess overlapping functions, 
substrate specificity is dictated by different tissue and cellular distribution (Steiner et al., 
1992). 
 
II.4.1-Tissue and cellular expression of PCs 
The tissue distribution and intracellular localization of PCs is varied as presented in 
Table 3. Furin and PC7 are widely distributed in the lymphatic system, in the liver and in the 
kidney, and are localized predominantly in endosomes, on the cell surface and in the trans-
Golgi Network (TGN) (Hatsuzawa et al., 1990; Schalken et al., 1987). PC5 and PACE4 are 
expressed in both endocrine and non-endocrine tissues, primarily in the brain, the digestive 
system and the adrenal cortex. They can be found intracellularly in the cell surface and in the 
extracellular matrix (ECM) (Lusson et al., 1993; Nakagawa et al., 1993). The expression of 
PC4 differs from other PCs since this enzyme is predominantly synthesized in testicular germ 
cells, the placenta and the ovary. PC4 is important in fertility, but its intracellular location is 
still not well characterized (Seidah and Prat, 2012; Torii et al., 1993). Neuronal and endocrine 
cells are rich in PC1 and PC2. They are found inside the cells in the TGN and are stored 
within the acidic regulated secretory vesicles (Seidah et al., 2008 and 1999). PC2 has been 
described to be the major protein convertase within the CNS (Seidah et al., 1998). 
Tissue and cellular location of PCs are fundamental in the determination of their role 
and target substrate. The rich expression of PC1 and PC2 in neuroendocrine cells confers a 
key role of these enzymes in the processing of several proneuropeptides and prohormones 
(Hook et al., 2008). 
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Protein convertase Tissue distribution Subcellular localization 
PC1 and PC2 Neuroendocrine Acidic regulated secretory granules 
Furin Ubiquitous TGN, cell surface, endosomes 
PC4 Germinal ?? 
PC5 Widespread: adrenal cortex, intestine, 
kidney,ovary Cell surface ECM 
PACE4 Widespread: muscle, heart, pituitary, 
intestine, cerebellum, kidney Cell surface ECM 
PC7 Ubiquitous TGN, cell surface, endosomes 
 
Table 3: PCs tissue distribution and subcellular location. Addapted from (Seidah and Prat, 2012).  
 
II.4.2-Proneuropeptide processing 
Bioactive neuropeptides usually result from the removal of N- or C-terminal residues, 
being commonly flanked by dibasic residues within the proneuropeptide sequence. C-
terminal and N-terminal proneuropeptide processing has been reported to be mediated by 
different proteases. PCs cleave at the C-terminal side and Cathepsin L at the N-terminal 
(Hook et al., 2008; Hook, 2006). The removal of basic residues from the intermediates differs 
between C- and N- terminal processing. Carboxypeptidases (CP), specifically 
carboxypeptidase E (CPE), removes basic residues from the C-terminal (Seidah and Prat, 
2002; Scamuffa, 2006). On the other hand, aminopeptidase is required for the removal of 
basic residues from the far N-terminal as shown in Figure 7 (Hook et al., 2008; Hwang et al., 
2007). The contribution of both pathways is controversial, and it has been suggested that the 
biosynthesis of most neuropeptides occurs by endoproteolytic cleavage on the C-terminal 
side (Zhang et al. 2010; Minokadeh et al. 2010).  
The main C-terminal peptide-processing endopeptidases identified in neuroendocrine 
tissues are PC1 and PC2. Their enzymatic activities have been extensively studied using a 
variety of approaches (Zhang et al., 2010; Miller, 2003; Breslin et al., 1993; Day et al., 1998; 
Johanning et al., 1998). PC1 and PC2 are often jointly involved in the production of a variety 
of neuropeptides due to their colocalization in neuroendocrine tissue. The role of PC2 was 
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extensively described and it was shown to be essential for the processing of a vast variety of 
proneuropeptides (Berman et al., 2000; Brakch et al., 1997; Paquet, 1996).  
PC1 and PC2 have been shown to efficiently cleave at dibasic sites, showing a 
primary affinity for dibasic KR residues, although cleavage at KK, RR, and RK dibasic sites 
have also been described (Hook et al., 2008; Berman et al., 2000; Day et al., 1998). Moreover, 
cleavage at monobasic R and K residues has been experimentally evidenced specially by PC2 
(Zhang et al., 2010; Day et al., 1998). Additionally, it has been suggested that paired basic 
amino acid residues can be cleaved in between basic amino acids (Hook and Bandeira, 2015). 
Due to their similar specificity and localization, PC1 has been reported to compensate for 
PC2 activity when the latter is absent (Miller et al., 2003), however the presence of other 
processing enzymes such as Cathepsin L makes this compensation difficult to be estimated. 
Factors including the substrate structure and localization of paired basic residues were 
reported to be important in the determination of PC specificity (i.e. enzyme-substrate 
complex thermodynamic stability) as occurs when a basic position is flanked by a proline at 
the C-terminal (Vanhoof et al., 1995; Breslin et al., 1993).  
 
 
Figure 7: Pathways for proneuropeptides processing (Hook, 2006). 
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Cathepsin L proteolytic processing occurs in parallel with reactions catalyzed by PC1 
and PC2. Cathepsin L is also present in secretory vesicles and contributes to the biosynthesis 
of neuropeptides. In this case, cleavage occurs at the N-terminal side of the dibasic residues, 
or between the dibasic residues (Hook, 2006; Hook et al., 2008; Yasothornsrikul et al., 2003). 
Overall, the synthesis of neuropeptides is dependent on a joint contribution of Cathepsin L, 
PC1 and PC2 to generate specific N- and C-terminal bioactive neuropeptides (Minokadeh et 
al., 2010). In contrast, the reduced concentrations of N-terminal derived neuropeptides in 
PC2 knockout mice suggest that PCs are also involved in N-terminal processing and reveal 
an alternative pathway to Cathepsin L (Zhang et al., 2010). 
 
II.4.3-Prodynorphin processing by PC1 and PC2 
Contrary to other opioid precursors such as PEnk and POMC (Loh et al., 2002; 
Johanning et al., 1998; Zhou et al., 1993), the study of PDyn processing presents an extra 
challenge because the formation of dynorphin peptides requires processing at dibasic and 
monobasic residues as shown in Figure 4.  
Just a few studies have examined the involvement of PC1 and PC2 in PDyn 
processing and mainly by in vitro techniques, using either purified recombinant enzymes or 
gene overexpression systems (Dupuy et al., 1994; Day et al., 1998). These studies have 
shown that both PC1 and PC2 are involved in PDyn processing and suggest a significant role 
of PC1 in the formation of a 10 kDa fragment resulting from PDyn dibasic processing. Trace 
amounts of an 8 kDa fragment were identified and shorter fragments from single basic 
processing were also observed. These data revealed an important contribution of PC1 to 
dibasic processing and a lesser role in monobasic processing of PDyn (Dupuy et al., 1994). 
In contrast, PC2 processing of PDyn was observed to generate notable amounts of shorter 
fragments including BDyn, Dyn 1-19, Dyn A, Dyn B and Dyn 1-8, in addition to the 
formation of the 10 kDa Dyn-containing fragment (Figure 8). These results demonstrated the 
ability of PC2 to cleave either at monobasic or dibasic residues. However, studies using 
recombinant enzymes and protein precursors are probably not representative of physiological 
conditions. The use of certain concentrations of enzymes and substrate may force 
thermodynamically unfavorable reactions due to entropic effects.  
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Interestingly, Berman and co-workers (Berman et al., 2000) studied PDyn processing 
using mice tissues lacking active PC2. By comparing with WT mice, the authors corroborated 
earlier findings, observing that under physiological conditions the concentration of 
dynorphin peptides, such as BDyn, Dyn A, Dyn B and Dyn 1-8 were considerably decreased 
whereas there was a significant increase in either unprocessed PDyn or high-molecular-
weight Dyn-containing fragments, such as the 10 or the 8 kDa fragments. 
 
 
Figure 8: Schematic representation of PDyn precursor shows possible paired and single basic 
cleavage sites (KR and R). Various processing intermediates, such as 10-, 8- and 4-(BDyn) kDa 
peptides were identified, as well as some final opioid peptide products such as Dyn A, Dyn B and 
Dyn 1-8. The shaded portions represent Leu-Enk (Berman et al., 2000). 
 
Later studies identified other dynorphin fragments, such as Dyn 1-13, Dyn 1-11, Dyn 
1-7 and Dyn 1-6, as Dyn A metabolic products by analyzing  in vivo cerebral microdialysates 
(Reed et al., 2003; Prokai et al., 1998).  
Considering the results outlined by these few studies, PC1 and PC2 appear to play a 
central role in the endoproteolytic processing of PDyn leading to the formation of several 
dynorphin metabolites including 10 and 8 kDa high-molecular-weight fragments, BDyn, Dyn 
1-19, Dyn A and Dyn B. However, the different contribution of PC1 and PC2 to PDyn 
processing showed in previous studies is still far from being clarified, and more importantly 
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the involvement of PC1 or PC2 in the metabolic turnover of bioactive dynorphins such as 
BDyn and Dyn A has never been studied. 
As shown in Figure 9, the presence of mono and dibasic residues on BDyn and Dyn 
A amino acid sequences suggest that, PC1 and PC2 could be involved in the regulation of 
BDyn and Dyn A endogenous levels and in the formation of several BDyn and Dyn A derived 
peptides. 
 
Figure 9: Potential BDyn and Dyn A-derived peptides from PC1 and PC2 cleavage 
 
II.4.4-PC1-/- and PC2-/- mice phenotypes 
The essential role of PC1 and PC2 in the synthesis of neuropeptides and hormones 
was also corroborated by several studies showing that PC1-knockout (PC1-/-) and PC2 
knockout (PC2-/-) mice presented several abnormalities associated with the deficient 
processing of hormones and neuropeptides. PC2-/- mutant mice were reported to exhibit 
elevated levels of unprocessed prohormones such as proinsulin (Furuta et al., 1997), 
proglucagon and prosomatostatin (Furuta et al., 2001; Laurent et al., 2002), as well as lesser 
amounts of several neuropeptides such as endorphins (Allen et al., 2001), enkephalins (Miller 
et al., 2003), and dynorphins (Berman et al., 2000). Even though these mice do not show 
significant differences on their survival rate compared with wild type (WT) animals, this 
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strain showed important reproductive problems (Furuta et al., 1997). On the other hand, PC1-
/- mice show several deficiencies of proneuropeptides and prohormones processing and a low 
survival rate, just a third of PC1-/- animals survive beyond seven days (Zhu et al., 2002). In 
particular, PC1-/- mice show grievous growth defects, presenting about 60% reduction of 
normal size at 10 weeks due to their lack of mature growth hormone (Lloyd et al., 2006; Zhu 
et al., 2002; Scamuffa et al., 2006). Furthermore, behavioral studies were performed on PC2-
/- animals to examine the consequences of PC2 deficiency on nociception and analgesia; 
interestingly, the PC2-/- mice were significantly less sensitive to pain (Croissandeau et al., 
2006).  
The behavioral responses observed in PC2 mutant mice to noxious stimulation were 
very similar to the behaviors presented by tachykinin-1-knockout (Tac1-/-) mice (Zimmer et 
al., 1998). Tac1 mutant mice present a deficiency of active SP, resulting in insensitivity to 
noxious perceptions. These observation, together with the reported involvement of PC2 on 
the formation of SP (Saidi et al., 2015), suggest that the behavioral responses observed in 
PC2-/- mice could be due to either the accumulation of intermediate opioid peptides with 
potent analgesic effects, or to a deficient formation of active nociceptive peptides such as SP 
(Croissandeau et al., 2006).  
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CHAPTER III-MASS SPECTROMETRY 
III.1-Introduction to mass spectrometry 
Mass spectrometry is a powerful analytical technique with high sensitivity and 
specificity for the identification and quantification of large and small molecules including 
peptides, proteins, lipids, and organometallic among other inorganic compounds (Yates et 
al., 2009; Becker, 2008; Hopfgartner et al., 2004; Colton et al., 1995). Mass spectrometers 
(MS) operate by converting analyte molecules into charged ions. Ionized analytes and any 
fragment ion produced are subsequently measured on the basis of their mass to charge ratio 
(m/z) (El-Aneed et al., 2009; Glish et al., 2003). 
A general schematic presentation of the main components of a MS instrument is 
presented in figure 10. At the ion source, analytes are converted into gas phase ions and 
transported through the interface by a high density electric field to the mass analyzer, where 
ions will be separated and identified according to their m/z. Ions are then ejected from the 
mass analyzer to the detector where the signal produced by the incident ions is transduced 
into output data represented as a mass spectrum (Ruse and Yates, 2006). 
Several different technologies are available for both the ionization and ion analysis 
depending on sample complexity and the goals of analysis, resulting in various types of mass 
spectrometers with specific capabilities (Glish et al., 2003). For the analysis of proteins and 
peptides, the combination of high performance liquid chromatography (HPLC) with an 
electrospray ionization-mass spectrometer (ESI-MS) has become the main tool in proteomic 
analysis owing to its high specificity, selectivity and its ability to handle complex mixtures. 
 
Figure 10: Schematic representation of the different sections of a MS system. 
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III.1.1-Sample separation  
The analysis of complex matrices such as biological fluids or tissues requires 
separation of analytes prior the analysis by mass spectrometry. A suitable separation provides 
a better efficiency of the ionization process, significantly improving the sensitivity (Cravatt, 
2007; Jemal and Xia, 1999). The most widely used technique for an efficient separation of 
peptides is HPLC. The HPLC system is interfaced to the MS via the ion source such as 
electrospray (ESI), which combines the separating power of HPLC, with the detection power 
of the MS. 
III.1.1.1-HPLC system 
HPLC was developed in the mid-1970's and rapidly gained popularity amongst 
analytical chemists due to the simplicity and the convenience of the technique. HPLC is a 
chromatographic technique used to separate components in a mixture based on their polarity 
and hydrophobicity (Bakes, 2000). This technique is based on the passage of the molecules 
contained in a sample carried by a mobile phase through a functionalized chromatographic 
column. The mobile phase is composed of a solvent or a mixture of solvents of a specific 
polarity and the column is packed with a stationary phase consisting of sorbent particles 
which are chemically functionalized (e.g. C18, C8, C4, Phenyl, CN) bound to a support, 
typically consisting of silica or polymers (Dorsey et al., 1998).  
According to the polarities of the analytes subject to chromatographic separation, 
both the mobile phase and the chromatographic column must be chosen to ensure that the 
analytes of interest are retained, but not so strongly that they cannot be eluted. For the 
chromatographic separation of nonpolar compounds or compounds with limited solubility in 
water, normal-phase liquid chromatography (NPLC) is used. This technique uses columns 
packed with polar stationary phases (CN, silica) combined with nonpolar or moderately-polar 
mobile phases (hexane, tetrahydrofuran) (William 2006). On the other hand, compounds 
containing functional groups which provide some degree of hydrophilic character to the 
molecule, are usually separated by reverse phase liquid chromatography (RPLC). Since a 
vast majority of compounds present a certain hydrophilic character, RPLC is the most 
commonly used separation technique in HPLC. This technique utilizes nonpolar stationary 
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phases (C18, C8), and aqueous-based polar mobile phases (water/methanol, 
water/acetonitrile). 
RPLC generally uses gradient elution when compounds with similar polarities need 
to be separated. A gradient elution refers to a variation on the polarity of the mobile phase 
during the chromatography. Thus, gradient-RPLC starts under aqueous conditions allowing 
the analytes to be strongly adsorbed to the surface of the stationary phase. By increasing the 
percentage of organic solvent on the mobile phase, each analyte is desorbed from the 
stationary phase within a very narrow variation on the concentration of organic solvent 
(Figure 11B) (Hodges and Mant, 1991; Kumar and Kumar, 2012). The elution order of the 
analytes is related to their hydrophobicity; more polar solutes move the fastest and appear 
first, followed by solutes of decreasing polarity (Figure 11B). 
 
Figure 11: (A) HPLC operating mode. The sample is injected into the system, the mobile phase is 
composed by a mixture of organic and aqueous solvents in a specific proportion and carry the 
sample into the column. The type of interaction between the molecule with the stationary and 
mobile phases makes each analyte to leave the column at different retention times 
(chromacademy.com). (B) Principle of RPLC with gradient elution (Kumar and Kumar, 2012). 
 
By the late 1970's, HPLC methods started to be developed and became popular especially in 
pharmaceutical laboratories to support the analysis and the isolation of molecules containing 
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similar functional groups using RPLC separation. HPLC was a new technique with 
significant improved separation, identification, purification and quantification features over 
previous chromatographic methods such as column chromatography or thin layer 
chromatography (Synder and Kirkland, 1979). Since then, continuous improvements in 
column packing material (Gritti and Guiochon, 2012), design of new instruments (Snyder et 
al., 2011) and development of computational methods and automation (Hanai, 2005) have 
improved the reproducibility, efficiency and robustness of this technique and simplified 
HPLC methods (Snyder, 2000).  
 
III.1.2-Sample Ionization  
Following HPLC separation, molecules need to be converted into gas phase ions prior 
to their introduction to the MS entrance. An atmospheric pressure ion source is necessary 
when any instrument that separates molecules in a liquid phase is coupled to a detector that 
identifies the ions by manipulations in the gas phase such as a MS. The ion source is needed 
to evaporate the liquid, produce ions and generate an electric field to transport the ions into 
the vacuum system of the mass spectrometer (Ashcroft, 1997). Due to its high ionization 
efficiency and its compatibility with HPLC fluidics, ESI has become the most popular 
technique capable of ionizing both small and large molecules of different polarities. 
Additionally, neutral or thermally stable molecules may require ionization by atmospheric 
pressure chemical ionization (APCI) or other related techniques (Carvalho et al., 2008; Nagy 
et al., 2007; Nelson et al., 2004). 
III.1.2.1-Electrospray Ionization  
ESI-MS was introduced by Yamashita and Fenn (1984) and has made a significant 
commercial impact since the 1990s (Balogh, 1998). In an ESI source, the liquid from the 
HPLC is directed through the free end of a capillary (electrode) set at 3 to 5 kV. In the case 
of pure ESI, the high electric field at the tip of the capillary pulls the liquid emanating from 
the electrode into a fine jet that breaks up, typically a millimeter from the tip of the electrode, 
into a fine spray of electrified droplets. Figure 12 illustrates the ESI process. 
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Figure 12: Schematic of a typical electrospray source 
 
The fine droplets in the spray, evaporate in about one millisecond to liberate charged 
molecules from the droplets as ions, which the electric field of the electrode tip then 
transports toward the entrance of the MS. Figure 13 illustrates the ionization and the 
evaporation mechanism involved during the ESI process.  
 
Figure 13: (A) HPLC eluent containing the sample analytes is sprayed into small droplets and 
converted into gas phase ions. The ions carried by the electric field and the high vacuum are then 
introduced through a transfer capillary into the MS. (B) The potential applied into the needle tip 
makes that the droplets of the same polarity are repelled from the needle towards the cone 
generating the so-called Taylor cone. As the droplets traverse the space between the needle tip and 
the cone, solvent evaporates until it reaches the point that the surface tension can no longer sustain 
the charge (the Rayleigh limit) at which point a "Coulombic explosion" occurs and the droplet is 
dissociated producing charged analyte molecules (Adapted from Gates, 2014). 
 
Currently, the ESI process is one of the softest ionization techniques available and has the 
advantage of generating molecular ions such as [M+nH]n+ or [M-nH]n-. The fact that the ions 
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observed in a given mass spectrum are produced in solution, and therefore no extra internal 
energy is imparted to the ions, makes ESI the most suitable ionization technique to convert 
analytes into gas phase ions without extensive degradation (Yates et al., 2009; Bruins et al., 
1987).   
Several other techniques were derived from this general concept such as ionspray or 
pneumatic assisted (Bruins et al., 1987), microspray (Covey, 1995) and nanospray (Wilm 
and Mann, 1996). Ionspray is the most often used version of ESI currently in bioanalysis, 
however the different techniques available encompass a wide range of nebulization capacities 
and flow rates.  
 
III.1.3-Mass analyzer 
Once the ions are generated at the ion source and introduced into the MS, ions are 
carried through the interface to the mass analyzer. The interface is made up of a series of 
optics, including skimmers, lenses and quadrupoles/octopoles that accelerate and focalize the 
ions from the atmospheric pressure zone, the ion source, to the mass analyzer which remains 
at high vacuum (Domon and Aebersold, 2006).  
The mass analyzer is the central component of a MS. It differentiates and separates 
the ions based on their relative m/z and progressively ejects the ions into the detector (Jansen 
et al., 2005). Several types of analyzers are available, the more frequently encountered ones 
for the analysis of proteins and peptides are quadrupole-based analyzers, time of flight (TOF) 
analyzers, ion traps and orbitraps (Mann et al., 2001). Moreover several hybrid instruments 
are also available. These instruments combine two or more mass analyzers providing a better 
sensitivity and ion separation than instruments equipped just with one analyzer. Hybrid 
instruments include, among others, the triple quadrupole (QqQ), the quadrupole coupled TOF 
(Q-TOF) and the quadrupole coupled orbitrap (Q-orbitrap) (Domon and Aebersold, 2006). 
Each instrument has its own features and depending on the desired application, the selection 
of the analyzer is an important step. 
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III.1.3.1-Quadrupole 
Quadrupole mass spectrometers have been widely used for many years. Generally, these 
devices are constructed from four parallel metallic rods. Radio frequency and direct current 
voltages are applied to the rods. The potential applied to adjacent rods are of the same 
magnitude but opposed, establishing a two-dimensional and dynamic electric field within the 
quadrupole. Mass selection is achieved by choosing a combination of radio frequency and 
direct current voltages such that ions within a narrow m/z are stable over the length of the 
quadrupole and reach the detector. Contrary, the ions which m/z differs from the range 
established are wasted (De Hoffmann et al., 2003) (Figure 14).  
 
Figure 14: Schematic illustration of a quadrupole mass analyzer 
(www.bris.ac.uk/nerclsmsf/techniques/gcms.html) 
 
The QqQ have been the traditional MS used on most analytical laboratories. The main 
feature of this instrument is its high detection sensitivity. This sensitivity is achieved though 
the combination of three quadrupoles arranged in series. The first and the third quadrupoles 
work as a mass filter allowing the passage of the ions within the selected m/z range. The 
second quadrupole consists of a collision cell where ions can be fragmented though their 
collision with an inert gas (N2, He), allowing the acquisition of MS2 spectra (Glish et al., 
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1982). MS2 (or MS/MS), consisting of a single fragmentation of a selected ion (precursor 
ion) and the subsequent analysis of its ion fragments, is the most used technique when 
structural information is required (Tozuka et al., 2003).   
III.1.3.2-Time of flight  
First time of flight (TOF) mass analyzers emerged in the 1960s but were soon replaced by 
quadrupole instruments owing to the lack of technologies to facilitate the recording and 
processing of the mass spectrum in a microsecond time-frame. Afterwards these facilitating 
technologies started to emerge and currently TOF analyzers are widely used for qualitative 
and quantitative high resolution analysis of small and large molecules (Guilhaus, 1995; Szájli 
et al., 2008). 
TOF mass analyzers work on the basis of measuring the time it takes for an ion to go over a 
distance when it is accelerated by an electric field of known strength. This acceleration results 
in an ion having the same kinetic energy as any other ion that has the same charge. However, 
for a given kinetic energy the velocity of the ion depends on its mass; the heavier the ions the 
lower the velocity. Thus, the time that the ion takes to cross a known distance of the flight 
path and reach the detector is measured (Figure 15). This time will depend on the m/z of the 
particle (Guilhaus et al., 2000).  
 
Figure 15: Schematic of a TOF mass analyzer 
The Q-TOF is the most widely used TOF-hybrid instrument which can be coupled with an 
ESI source. It consists of the combination of a triple quadrupole coupled with a TOF analyzer. 
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This instrument has the highest selectivity, resolution and mass precision features among the 
different mass spectrometers, however, its detection limit is lower (Williamson and Bartlett, 
2007; Bristow, 2006). 
III.1.3.3-Ion traps 
One of the first linear traps was constructed by Church (1969). Nowadays, ion trap 
mass analyzers are widely used for the analysis of small and large molecules, and its main 
feature is its high sensitivity particularly for untargeted analysis (Douglas et al., 2005).  
Ion trap analyzers work on the basis of storing ions in a “trap” and manipulating the 
ions by using static and radio frequency voltages. The amplitude of the applied voltages 
enables the analyzer to trap ions of specified m/z within the analyzer, and non-selected ions 
are given a trajectory by the electrostatic field that causes them to exit the trap (Payne and 
Glish, 2005). Ions contained inside the trap are then sequentially ejected based on their m/z 
values to the detector to create a mass spectrum (Figure 16). Alternatively, a specific ion can 
be isolated into the trap by the application of a specific voltage while other ions are ejected. 
By filling the trap with an inert gas such as N2 or He, fragmentation of those selected ions is 
possible. This isolation and fragmentation can be performed several times in succession 
before the final mass spectrum is obtained, resulting in a so called MSn spectrum.  
 
Figure 16: Schematic representation of an ion trap mass analyzer. Ions of a specified m/z are trap 
in the analyzer. Non-selected ions are ejected from the trap (adapted from 
www.york.ac.uk/chemistry/staff/resstaff/yoshikawan) 
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Two different ion trap mass analyzers are available: 3D-ion trap, and linear ion trap. 
They differ in their design and geometry as well as their features, but their working principle 
is complementary. In most of cases, linear ion traps provide higher sensitivity, resolution and 
mass precision compared to 3D ion traps (Hager, 2002; Schwartz, 2002). Ion traps can be 
combined with other mass analyzers in hybrid instruments. The LTQ-XL from Thermo 
Scientific, combines a linear ion trap with a quadrupole which allows the isolation of a 
desired m/z range ions to reach the ion trap, thus improving the sensitivity of the analysis 
(Hager, 2002). 
III.1.3.4-Orbitrap  
The Orbitrap was first presented to the general MS public at a conference of the 
American Society for Mass Spectrometry in 1999. It quickly made its debut in mainstream 
MS in 2005 as an accurate and compact mass analyzer (Makarov et al., 2006).  
Orbitrap mass analyzers operate by making the ions oscillate around a central barrel-
like electrode sustained at high voltage. The strong electrical field inside the trap generated 
by the central electrode initiates the axial oscillations of the ions, whose harmonic frequency 
oscillation along the electric field axis is then measured. Since the ion oscillation frequency 
is proportional to the ion m/z, fast Fourier transform calculations allows the conversion of 
the detected oscillating signal is into a mass spectrum (Figure 17). 
Orbitrap mass analyzers provide high performance and high resolution (i.e. 140 000 
FWHM and < 3 ppm mass precision) analysis. The high resolution powers of this type of 
analyzer provides high resolution MS spectra, from where the exact mass and the isotopic 
distribution of the ions can be accurately determined (Van der Heeft et al, 2009). The wide 
range of applications of this analyzer and its performance characteristics, including its high 
resolution, high mass accuracy, dynamic range and tandem MS capabilities, makes this 
analyzer one of the most powerful and commercially claimed MS instrumentation of the last 
decade (Hardman and Makarov, 2003). Hybrid Orbitrap instruments, such as the Q-Exactive 
from Thermo Science, combine the Orbitrap with a quadrupole allowing an early m/z range 
selection, a collision cell where ions can be fragmented and an ion trap (C-trap) that 
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progressively injects the ions fragmented or selected into the Orbitrap analyzer (Michalski et 
al., 2011; Hu et al., 2005). 
 
Figure 17: Orbitrap operating basis. Ions are injected into the Orbitrap, where, as a consequence 
of the high voltage applied on the central electrode, ions oscillate around the electrode driven by 
the strong electric field inside the Orbitrap. Ions oscillation frequency is then measured and 
converted into a useful signal.  
 
III.1.4-Ion Detector  
The final element of the mass spectrometer is the detector, except for instruments 
based on Orbitrap mass analyzer where the detector is embedded in the analyzer. Once the 
ions have passed the mass analyzer, they have to be detected and transformed into a usable 
signal. The detector is an important element of the mass spectrometer that generates a signal 
from incident ions. Electron multipliers are the most commonly used detectors. These types 
of detector are made up of a series of dynodes which generates an amount of secondary 
electrons that are proportional to the number of incident ions. Those secondary electrons are 
then focalized to further dynodes that will amplify the signal. Electrons will finally fall upon 
an electron collector anode, transducing the signal into data (Gaire et al., 2007; Funsten et 
al., 2005; Céolin et al., 2005). 
 
III.1.5-Nomenclature for peptide fragmentation  
MS2 (also MS3) analysis is the most frequent operating mode for qualitative and 
quantitative MS analysis of proteins and peptides. It is especially useful when structural 
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information is required. The ion fragments generated during the fragmentation process are 
named in accordance to the position where the peptide or protein was fragmented. As shown 
in Figure 18, the fragments produced from fragmentation at the peptide bound between two 
amino acids are called “y”, for C-terminal fragments, and “b” fragments, for N-terminal 
fragments. When fragmentation occurs between the chiral carbon and the carbonyl group 
within a specific amino acid, “x” and “a” fragments are obtained. Lastly, if the fragmentation 
takes place between the amide group and the chiral carbon of amino acids “z” C-terminal 
fragments and “c” N-terminal fragments are obtained. In addition, fragments are numbered 
in accordance to the position of the amino acid subject to fragmentation within the amino 
acid sequence of the peptide. 
Thus, as an example, the b4 fragment observed in the MS/MS spectra obtained for 
Leu-Enk (YGGFL) singly charged ion (pg. 75), corresponds to the fragment GGFL generated 
by the brake down of the peptide bound between Y and G amino acids. 
 
Figure 18: Peptide fragmentation nomenclature 
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III.1.6-MS data acquisition modes  
III.1.6.1-Full scan MS mode 
Full scan mode allows the monitoring of ions comprised on a set m/z range (Figure 
19A). A typical mass scan range will cover from 200-2000 m/z (5 to 10 Hz) and will detect 
ions within that range over a set time period typically fixed according to HPLC conditions. 
Several molecule libraries are available, including extensive protein and peptide databases 
containing experimental and in silico generated mass spectra used for analyte identification 
and characterization (Mueller et al., 2008; Perkins et al., 1999). The Full scan mode is very 
useful when identifying unknown compounds in a sample or indispensable for untargeted 
assays (Rossi and Sinz, 2001). Moreover, working on Full scan mode with high resolution 
mass analyzers such as Orbitraps, allows the identification of peaks by observing the exact 
mass (< 3 ppm) and the isotopic distribution of the specific ion, tools that can be used to 
reduce false positive identification (Van der Heeft et al, 2009).  
III.1.6.2-SRM and MRM modes 
The basic concept of single reaction monitoring (SRM) and multiple reaction 
monitoring (MRM) modes is to monitor the presence and intensity of a specific transition of 
a selected precursor ion, which is isolated in the mass analyzer, into a single or multiple 
fragment ions (Figure 19B). The double selection criteria (precursor/fragment ions) provide 
high specificity for peptide detection since any undesired transitions can be avoided. 
Furthermore, dependent MSn scans can be used to provide further sequence information for 
the selected peptides, thus increasing the specificity of the technique. The use of SRM or 
MRM has a compromise in that SRM analysis provides lower detection limits whereas MRM 
provide higher selectivity and specificity (Addona et al., 2009; Keshishian et al., 2007). Its 
selectivity and specificity features make this operation mode ideal for quantitative analysis. 
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Figure 19: (A) Full scan acquisition mode. All ions generated at the ions source are injected into 
the detector. The total ion chromatogram (TIC) shows all the ions detected on the basis of their 
retention time. (B) SRM and MRM mode. Specific m/z ions are selected and fragmented. Extract ion 
chromatogram (XIC) is extracted by monitoring a specific transition. A specific ion (precursor ion) 
is selected and fragmented. Then, one (SRM) or more (MRM) of its fragment ions generated, are 
isolated and injected into the detector. This operating mode also allows to obtain structural 
information from the MS2 spectra by studying the fragmentation pattern. 
 
III.1.7-Absolute quantification by isotope dilution 
Isotope dilution has been used for several decades for the quantitative analysis of 
proteins and peptides by HPLC-MS (De Leenheer and Thienpont, 1992) and has been 
recognized as the reference method for internal standardization (Brun et al., 2009). The 
absolute quantification by isotope dilution is based on the addition of defined quantities of 
isotopically label standards which are created by the substitution of specific atoms for one of 
its isotopes. The most common labeling comprises the substitution of 1H by 2H (d) or 12C by 
13C. These labeled standards exhibit the same chromatographic and ionization behavior as 
the unlabeled peptide, but they can be distinguished by their mass difference (Figure 20) and 
isotopic signature (Ong and Mann, 2005). Thus, independent extract ion chromatograms 
(XICs) can be extracted from selecting the same parent ion or the same MS2 transition for the 
unlabeled and labeled peptides. The concentration of the targeted peptides in the sample can 
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be determined by using the peak area ratio in a biological sample (Keshishian, 2007). The 
most important advantage of this quantitative technique is the alleviation of the matrix effect 
that might take place during the ionization process since both peptides are ionized with the 
same efficiency (Pailleux and Beaudry, 2012). 
 
Figure 20: Leu-Enk MS2 spectra shows how the peaks corresponding to the fragment ions from the 
unlabeled standard and the labeled peptide can be differentiated owing to the differences 
between their masses. XICs are extracted for each peptide by monitoring the same specific MRM 
transition for both peptides.  
 
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS AND OBJECTIVES 
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The endoproteolytic regulation of BDyn and Dyn A levels has a profound impact on 
pain perception.  Nevertheless, the role of PCs in the regulation of BDyn and Dyn A levels 
remains unclear. Both BDyn and Dyn A contain paired or single basic residues where PCs 
could be involved in their C-terminal processing, leading to several important N-terminal 
metabolites. It is hereby hypothesized that PC1 and PC2 are crucial for BDyn and Dyn A 
processing through cleavage at these basic positions. In addition, the presence of one copy 
of Leu-Enk at the N-terminal of dynorphin peptides, suggest that Leu-Enk could be an 
important metabolic product of BDyn and Dyn A processing. 
The objectives of this study were to elucidate the role of PC1 and PC2 in the 
proteolytic control of BDyn and Dyn A levels. For this purpose, S9 cellular fractions of mice 
spinal cords were used to perform the in vitro digestion of BDyn and Dyn A. Differences in 
the activity of PC1 and PC2 were evaluated by comparing the metabolism in spinal cord S9 
fractions obtained from WT versus PC1(-/+)/PC2(-/+) animals. Thereafter, an HPLC-MS/MS 
method was developed to characterize BDyn and Dyn A metabolites and an isotope dilution 
method was used for their quantitation. 
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Abstract 
Dynorphins are important neuropeptides with a central role in nociception and pain 
alleviation. Many mechanisms regulate endogenous dynorphin concentrations, including 
proteolysis. Proprotein convertases (PCs) are widely expressed in the central nervous system 
and specifically cleave at C-terminal of either a pair of basic amino acids, or a single basic 
residue. The proteolysis control of endogenous Big Dynorphin (BDyn) and Dynorphin A 
(Dyn A) levels has a profound impact on pain perception and the role of PCs remain unclear. 
The objective of this study was to decipher the role of PC1 and PC2 in the proteolysis control 
of BDyn and Dyn A levels using cellular fractions of spinal cords from wild type (WT), PC1-
/+ and PC2-/+ animals and mass spectrometry. Our results clearly demonstrate that both PC1 
and PC2 are involved in the proteolysis regulation of BDyn and Dyn A with a more important 
role for PC1. C-terminal processing of BDyn generates specific peptide fragments Dynorphin 
1-19, Dynorphin 1-13, Dynorphin 1-11 and Dynorphin 1-7 and C-terminal processing of Dyn 
A generates Dynorphin 1-13, Dynorphin 1-11 and Dynorphin 1-7, all these peptide fragments 
are associated with PC1 or PC2 processing. Moreover, proteolysis of BDyn leads to the 
formation of Dyn A and Leu-Enk, two important opioid peptides. The rate of formation of 
both is significantly reduced in cellular fractions of spinal cord mutant mice. As a 
consequence, even partial inhibition of PC1 or PC2 may impair the endogenous opioid 
system.   
Keywords: Dynorphins, Dynorphin A, Proprotein convertases, Proteolysis, Opioid 
Peptides, Spinal cords, Mass spectrometry  
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1. Introduction 
In mammals, the presences of tissue-damaging stimuli are sensed by primary afferent 
nociceptors. The sensation of pain produced by a noxious stimulus is not always consistent 
and depends on numerous factors influencing the neurophysiology of pain transmission 
(Julius and Basbaum, 2001; Gold, M.S. and Gebhart 2010). The nervous system has 
developed very complex mechanisms that control how noxious sensory input is perceived by 
the organism (Basbaum et al., 2009). It has been shown that extensive modulation of sensory 
information happens in the dorsal horn of the spinal cord, more specifically at the first 
synapse (Honore et al., 2000; Levine et al., 1993). There are various molecular events 
contributing to the transmission of the sensory information at the first synapse and several 
major neuropeptides were identified including dynorphin, enkephalin and tachykinin 
peptides (Kuner, 2010; Mika et al., 2011; Felippotti et al., 2012; Pailleux et al., 2013; Ferland 
et al., 2011).  
Neuropeptides are either neurotransmitters or neuromodulators at various levels in the central 
nervous system and play a critical role in pain transmission (Levine et al., 1993; Seybold, 
2009). Many members of the tachykinin family (e.g. Substance P) are mostly pro-nociceptive 
neuropeptides and have been known to play a fundamental role in central sensitization 
leading to hyperalgesia and allodynia (Lecci et al., 2000; Teodoro et al., 2013). Opioid 
peptides (i.e. endomorphins, enkephalins and dynorphins) have potent analgesic effects in 
the central nervous system (CNS) and play a fundamental role in endogenous pain inhibition 
(Machelska, 2007; Wahlert et al., 2013; Bali et al., 2014). They are interacting with μ, κ and 
δ-opioid receptors expressed widely in the brain and in the spinal cord (Carr and Lovering, 
2000; Stanojevic et al., 2008; Mulder et al., 1989).  
Dynorphin A (Dyn A), one of the major proteolytic fragments of prodynorphin (Civelli et 
al., 1985; Dores et al., 1985), is an endogenous ligand of the κ and μ-opioid receptors 
(Beaulieu et al., 2005; Mika et al., 2011). The agonist activity of Dyn A significantly reduces 
neuronal activity (Chavkin et al., 1982; Mizoguchi et al., 2006). However, the concentration 
of Dyn A in the spinal cord can be regulated rapidly by endoproteolysis (Cho and Basbaum, 
1989). Neuropeptides are derived from larger protein precursors (i.e. proneuropeptides) and 
their primary structures include the sequence of the active form of at least one neuropeptide 
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within its full-length (Funkelstein et al., 2010). It has been revealed that many neuropeptides 
are synthesized by the actions of protein convertases (PCs) and endopeptidases within dense 
core vesicle (Harrison and Geppetti, 2001). Particularly, recent studies outlined the 
significant contribution of PC1 and PC2 into the proteolytic processing of proneuropeptides 
(Zheng et al., 1994; Cui et al., 1998; Jin et al., 2005; Miller et al., 2003). PCs, particularly 
PC1 and PC2 are widely expressed in the CNS and specifically cleave at C-terminal of either 
a pair of basic amino acids (KR-, RR-, RK- and KK-), or a single basic residue (R or K). 
Early prodynorphin (PDYN) endoproteolytic studies suggest that PCs play a significant role 
in PDYN processing (Berman et al., 2000; Day et al., 1998). These preliminary results 
generated using indirect methods suggest that the action of PC2 is needed for the formation 
of Big dynorphin (BDyn), Dyn A and dynorphin B (Dyn B) (Day et al., 1998). The 
proteolytic control of endogenous BDyn and Dyn A levels has a profound impact on pain 
perception and the role of PCs remain unclear.  As shown in Figure 1, both peptides contain 
paired or single basic residues and the action of PCs could be involved in C-terminal 
processing of BDyn and Dyn A leading to several important N-terminal metabolites. 
Interestingly, BDyn, Dyn A and all N-terminal metabolites encode one copy of Leu-
enkephalin (Leu-Enk), an important opioid peptide. The objective of this study was to 
decipher the role of PC1 and PC2 in the proteolysis control of BDyn and Dyn A levels using 
cellular fractions of spinal cords from wild type (WT), PC1-/+ and PC2-/+ animals.  
2. Materials and Methods 
2.1 Chemicals and reagents 
Big Dynorphin (BDyn), Dynorphin A (Dyn A), Dynorphin 1-13 (Dyn 1-13), Dynorphin 1-
11 (Dyn 1-11), Dynorphin 1-10 (Dyn 1-10), Dynorphin 1-9 (Dyn 1-9), Dynorphin 1-7 (Dyn 
1-7), Dynorphin 1-6 (Dyn 1-6) and Leu-Enkephalin (Leu-Enk) were purchased from Phoenix 
Pharmaceuticals (Belmont, CA, USA). Dynorphin 1-19 (Dyn 1-19) and deuterium labeled 
analogue peptides were synthesized de novo (CanPeptide, Inc., Pointe-Claire, QC, Canada). 
Other chemicals, including acetonitrile, hexane, formic acid, Trifluoroacetic acid (TFA), 
sodium phosphate dibasic and sodium phosphate monobasic were purchased from Fisher 
Scientific (Ottawa, ON, Canada).  
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2.2 Sample Preparation 
Spinal cord tissues (n=6 per genotypes) from male WT (C57BL/6J), male PC1-/+ (product 
#006327) and male PC2-/+ mice (product #002963) were obtained from The Jackson 
Laboratory (Bar Harbor, Maine, USA) and kept frozen at -80 °C until analysis. Heterozygote 
animals only were used since PC1-/- and PC2-/- exhibit many abnormalities and the survival 
rate after one week is extremely low. Animal genotyping was performed for each animal by 
Jackson Laboratory using a standard PCR assay. All mice were 8 weeks old at time of tissues 
collection. The animals from all groups (WT, PC1-/+ and PC2-/+) were euthanized with an 
overdose of isoflurane followed by a transection of the cervical spine. A flush of saline was 
performed within the spinal canal to collect the spinal cord lumbar enlargement. Tissue 
samples were snap-frozen in cold hexane (-60 °C) and stored immediately at -80 °C pending 
analyses. The study protocol was approved by the Institutional Animal Care and Use 
Committee of the Faculty of Veterinary Medicine of the Université de Montréal and it was 
performed in accordance with the guidelines of the Canadian Council on Animal Care. 
For each animal group, three spinal cords were pooled and homogenized in a 0.1 M phosphate 
buffer, pH 7.4 at a ratio of 1:5 (w:v). Samples were sonicated 20 minutes and the 
homogenates were centrifuged at 9,000 g for 10 minutes. The total amount of protein in each 
supernatant was determined using the standard Coomassie protein assay (Bradford). This 
procedure was necessary in order to assure the same amount of protein was used for each 
experiments. Supernatant aliquots, designated as S9 fractions, were kept at -80 °C until 
usage.  
2.3 Peptide metabolism study  
The incubations were performed minimally in triplicate. The incubations were performed in 
a microcentrifuge tubes and contained 2.5 nmol/mL of BDyn or Dyn A, 0.25 mg/mL of S9 
fraction proteins diluted in 0.1 M phosphate buffer, pH 7.4. Spinal cord S9 enzyme 
suspensions (total volume of 1 mL) were preincubated with 1mM CaCl2 in 0.1 M phosphate 
buffer (pH 7.4) at 37°C for 5 min prior fortification with BDyn or Dyn A. Immediately after 
fortification of the full-length peptide into the spinal cord S9 fraction suspension containing 
1mM CaCl2, the sampling point for t=0 was taken, and the reaction was quenched after 30 
minutes incubation. Two hundred microliters of samples were taken and mixed with 200 µL 
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of an aqueous solution containing 1% TFA to stop the reaction. Samples were centrifuged at 
12,000 g for 10 min and 150 μL of the supernatant was transferred into an injection vial and 
spiked with 150 µL of the deuterated internal standard solution (50 pmol/mL labeled peptides 
in 0.1% TFA) for MS analysis. The rate of formation (vi) was calculated based on the 
concentration of each metabolite measured after 30 minutes incubation of the full-length 
peptides using Equation 1. 
𝑣𝑣𝑖𝑖 = 𝑑𝑑[𝑃𝑃]𝑑𝑑𝑑𝑑 = [𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑖𝑖𝑑𝑑𝑝𝑝 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑝𝑝𝑓𝑓𝑑𝑑𝑓𝑓]30 𝑓𝑓𝑖𝑖𝑓𝑓   (1) 
2.4 Instrumentation 
The HPLC-MS/MS system included a Thermo Accela autosampler, a Thermo Accela pump 
and a Thermo LTQ-XL Linear Ion Trap Mass Spectrometer (San Jose, CA, USA). Linear ion 
trap instruments typically have unit mass resolution throughout the mass range. The 
instrument was calibrated and the resolution was set at 0.5-0.7 Da at full width at half 
maximum (FWHM). Data were acquired and analyzed with Xcalibur 2.2 (San Jose, CA, 
USA), and regression analyses were performed with PRISM (version 6.0d) GraphPad 
software (La Jolla, CA, USA) using nonlinear curve-fitting module with an estimation of the 
goodness of fit. The calibration lines were constructed from the peak-area ratios of targeted 
neuropeptides and corresponding deuterated labeled peptides used as internal standards. 
Further analyses were performed using a Thermo Scientific Q-Exactive Orbitrap Mass 
Spectrometer (San Jose, CA, USA) interfaced with a Thermo Scientific UltiMate 3000 Rapid 
Separation UHPLC system using a pneumatic assisted heated electrospray ion source.  
 
2.5 Bioanalytical methods 
The chromatography was achieved using a gradient mobile phase along with a microbore 
column Thermo Biobasic C8 100 × 1 mm, with a particle size of 5 μm. The initial mobile 
phase condition consisted of acetonitrile and water (both fortified with 0.1% of formic acid) 
at a ratio of 5:95. From 0 to 1 min, the ratio was maintained at 5:95. From 1 to 12 min, a 
linear gradient was applied up to a ratio of 45:55 and maintained for 3 min. The mobile phase 
composition ratio was reverted at the initial conditions and the column was allowed to re-
equilibrate for 15 min for a total run time of 32 min. The flow rate was fixed at 75 µL/min 
and 2 µL of sample were injected using full loop mode. All targeted neuropeptides and 
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deuterium labeled peptides eluted between 6.2 to 9.3 min. The mass spectrometer was 
coupled with the HPLC system using a pneumatically assisted electrospray ion source (ESI). 
The sheath gas was set to 25 units and the ESI electrode was set to 4000 V in positive mode. 
The capillary temperature was set at 300°C and the ion transfer tube voltage to 46 V. All scan 
events were acquired with a 100 ms maximum injection time. An activation q = 0.25 and 
activation time of 30 ms were used for all targeted peptides. The mass spectrometer operated 
for quantitative analyses in full scan MS/MS and the quantification was based on specific 
post-processing multiple reaction monitoring (MRM) extracted ion chromatograms. Specific 
analysis details are presented in Table 1. Two specific production ions were used to generate 
post acquisition MRM extracted ion chromatograms for quantification purposes. The method 
used an isotope dilution mass spectrometry (IDMS) strategy for the quantification of the 
targeted peptides. Due to synthesis yield issues related to generate labeled BDyn and Dyn 1-
19, deuterated Dyn A was used as an internal standard for BDyn and Dyn 1-19 quantification 
along with the BDyn and Dyn 1-19 reference standards. The labeled peptides were used at a 
constant concentration of 50 pmol/mL. The peptide concentrations were determined using 
the peak area ratio of the light and heavy analog peptide. Additional analyses were performed 
using a hybrid Quadrupole-Orbitrap mass spectrometer (i.e. Thermo Q-Exactive). The 
chromatographic condition used was identical. The MS detection was performed in positive 
ion mode and it was operating in full-scan mode at high-resolution, and accurate-mass 
(HRAM). Nitrogen was used for sheath and auxiliary gases and they were set at 10 and 5 
arbitrary units. The ESI probe was set to 4000 V and the ion transfer tube temperature was 
set to 300°C. The scan range was set to m/z 300-1500. Data was acquired at a resolving power 
of 140,000 (FWHM), resulting to a scanning rate of ≈ 700 msec/scan when using automatic 
gain control target of 3.0x106 and maximum ion injection time of 200 msec. 
 
 
 
2.6 Statistical analysis 
All data were analyzed using a one-way ANOVA followed by Dunnett multiple comparison 
test. Significance was set a priori to p < 0.05. The statistical analyses were performed using 
PRISM (version 6.0f). 
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3. Results and Discussion 
3.1 Mass Spectrometry and Isotopic Dilution Method 
 
Full-scan and product ion mass spectra for all peptides and internal standards were obtained 
in positive ion mode. The full-scan electrospray mass spectrum of targeted peptides displayed 
the formation of characteristic pseudo molecular ions [M+nH]n+ and the fragment ions 
observed in MS/MS spectra were annotated based on the Roepstorff and Fohlman 
nomenclature (Roepstorff and Fohlman, 1984). Details on MS parameters and MRM 
transitions are reported in Table 1. Full-scan and product ion mass spectra are necessary to 
identify and characterize each neuropeptide. The full-scan electrospray mass spectra of 
targeted neuropeptides showed a base peak pseudo molecular ions at m/z 569.9 (7+) for 
BDyn, 487.1 (+5) for Dyn 1-19, 716.4 (+3) for Dyn A, 535.3 (+3) for Dyn 1-13, 682.0 (+2) 
for Dyn 1-11, 617.9 (+2) for Dyn 1-10, 434.7 (+2) for Dyn 1-7, 356.7 (+2) for Dyn 1-6 and 
556.3 (+1) for Leu-Enk. Corresponding labeled peptides shown compatible pseudo molecular 
ion profiles. All precursor ion masses are listed for each unlabeled and labeled peptide in 
Table 1. Figure 2 presents product ion spectra (MS/MS) for targeted neuropeptides obtained 
and typical a, b, c, y and z positive ion fragments were observed. The observed collision-
induced dissociation spectra were all compatible with the neuropeptide sequences. 
Additionally, we selected and optimized two of the most abundant and specific product ions 
for each neuropeptide to generate post acquisition MRM extracted ion chromatograms in 
order to achieve the best sensitivity, selectivity and reproducibility. Furthermore, selected 
MRM transitions were monitored for spinal cord S9 fraction supernatants and compared with 
reference materials. The overlay MRM extracted ion chromatograms display in Figure 3 
demonstrate a good concordance between peptide reference standards and peptides observed 
in spinal cord S9 fraction supernatants. Due to the important dilution factor of spinal cord S9 
fraction used during this study, the endogenous levels were below the limit of quantification.  
The heavy-label versions of Dyn A, Dyn 1-11, Dyn 1-10, Dyn 1-9, Dyn 1-7, Dyn 1-6 and 
Leu-Enk were spiked in spinal cord S9 fraction supernatants to quantify BDyn and Dyn A 
metabolites.  After optimization, the concentration of spiked labeled peptides, it was 
determined that a final concentration of 50 pmol/mL would lead to adequate measurements 
of the peptides selected MRM transitions. All labeled peptides are clearly distinguishable 
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from unlabeled version by mass spectrometry, and the ratio of the unlabeled peptides to stable 
isotope-labeled peptides found in mouse spinal cord S9 fraction supernatants can be used to 
calculate the absolute concentration of each peptide monitored. The linearity response was 
tested at concentration ranging from 1 to 200 pmol/mL for each peptide. Correlation 
assessments between measured peak area ratios and nominal dilution ratios were performed 
and results show excellent correlations (R2 = 0.9906 to 0.9999). The precision (%CV) was 
comprised between 1.3% and 9.1% and the accuracy (%NOM) was contained between 88.2% 
and 110.9% for all targeted neuropeptides. Accordingly, the analytical method provided 
adequate figures of merit for targeted peptide analysis performed during this study. 
3.2 Metabolic stability of BDyn and Dyn A in mouse spinal cord S9 fractions 
Big dynorphin and Dyn A concentration in mouse spinal cord is regulated by proteolysis 
generating a series of peptide metabolites. Tissue S9 fractions are widely used to study 
metabolism since this fraction contains the cytosol and microsomes (Duffus et al., 2007). To 
determine the pathways for BDyn and Dyn A degradation in mouse spinal cord S9 fractions, 
spinal cord S9 fractions were incubated with full-length BDyn and Dyn A for 30 min and 
then analyzed the quenched reactions by HPLC-MS/MS (i.e. Thermo LTQ-XL) to determine 
BDyn and Dyn A metabolic stability and identify fragments that had been produced. The 
Figure 4 revealed that proteolysis of BDyn and Dyn A is occurring in mouse spinal cord S9 
fractions. The results shown that > 86% of the full-length peptides degraded in 30 minutes. 
Furthermore, negative control (i.e. no S9 proteins) shows no degradation after a 30 minutes 
incubation period for both full-length peptides. These results revealed significant BDyn and 
Dyn A degrading activity in mouse spinal cord S9 fractions.  
3.3 Metabolite profiling using HRAM MS analysis 
Neuropeptides are generally synthesized as larger precursors that undergo endoproteolysis at 
specific sites. Several neuropeptide-processing enzymes were identified in mammalian cells 
(Fricker and Devi, 1995). Endoprotease of the subtilisin family of serine proteases, including 
proprotein convertases (PCs), cleave peptide precursors at paired or single basic residue 
(Conn and Smith, 1995; Minokadeh et al., 2010). Following the precursor cleavage at paired 
or single basic residue, carboxypeptidases remove basic amino acids from the C-terminal 
61 
 
 
 
(Zheng et al., 1994; Fricker, 1988) of the resulting metabolites (Hook et al. 2008). As shown 
in Figure 1, schematic representation of BDyn and Dyn A indicates possible paired and single 
basic cleavage sites. Full-length peptides, BDyn and Dyn A, were incubated for 30 minutes 
in mouse spinal cord S9 fractions and following the reaction termination, supernatant were 
analyzed using a Quadrupole-Orbitrap high-resolution mass spectrometer.  The HRAM MS 
analysis reveals specifically the presence of several expected BDyn and Dyn A metabolites 
with mass accuracy within 2 ppm as shown in Table 2 and 3. Many expected and targeted 
PC1 and PC2 primary and secondary metabolites were detected. Interestingly, following the 
degradation of BDyn, we can detect the presence of Dynorphin B but also Dyn 12-32 and 
Dyn 14-32, two complementary metabolites of Dyn 1-11 and Dyn 1-13. This result suggests 
that Dyn 1-11 may not be sequentially produced following the formation of Dyn 1-13.  
Interestingly, C-terminal processing of Dyn A leads to the formation of N-terminal fragments 
Dyn 1-13, Dyn 1-11 and Dyn 1-7, all potential metabolites resulting from PC1 or PC2 
cleavage. Additionally, we were able to detect complementary C-terminal fragments 
including Dyn 14-17, Dyn 12-17 and Dyn 8-17 denoting they are most likely primary 
cleavage products. Our results clearly revealed the presence of BDyn and Dyn A metabolites 
compatible with PC1 or PC2 processing.  N-terminal processing at dibasic residue by 
cathepsin L was reported to be involved for the production of enkephalin peptides (Hook et 
al., 2008; Funkelstein et al., 2010). HRAM MS analysis reveals the presence of Leu-Enk 
following BDyn and Dyn A incubation in mouse spinal cord S9 fractions. No other 
significant peaks associated with N-terminal processing at dibasic residue were observed. 
Leu-Enk can be directly produce by cathepsin L N-terminal processing of  BDyn and Dyn A 
or by C-terminal processing of Dyn 1-7, an important C-terminal processing metabolite 
observed.   
3.4 Analysis of PC1 and PC2 in mouse spinal cord S9 fractions  
We have previously performed the quantification of PC1 and PC2 in WT, PC1-/+ and PC2-/+ 
mouse spinal cord S9 fractions (Saidi et al., 2015). Briefly, we quantified PC1 and PC2 in 
WT, PC1-/+ and PC2-/+ mouse spinal cord S9 fractions using high-resolution MS. The 
analytical strategy was based on a targeted peptide mass fingerprinting (PMF) method that 
specifically relies on upstream identification of specific PC1 and PC2 proteolytic peptides 
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using in silico digestion to generate a mass list. The protein analyses were performed using 
a hybrid Quadrupole-Orbitrap mass spectrometer operating in MS at a resolution of 140,000 
(FWHM) and in MS/MS at a resolution of 17,500 (FWHM). Two specific proteolytic 
peptides for PC1 and PC2 were observed within 1 ppm of the exact mass. Specific XIC's 
(exact mass ± 5 ppm) of each targeted proteotypic peptides were used to perform label-free 
relative quantification based on observed ion abundance. Our results reveal that PC1 and PC2 
are significantly down-regulated (i.e. 38 to 49%) in PC1-/+ and PC2-/+ mouse spinal cord S9 
fractions respectively (Saidi et al., 2015). Additionally, all collected MS/MS spectra were 
coherent with the amino acid sequence of each tryptic peptide. 
3.5 Contribution of PC1 and PC2 in BDyn C-terminal processing 
Some studies have examined the involvement of PC1 and PC2 in PDYN processing but none 
have shown the involvement of PC1 or PC2 in the metabolic turnover of BDyn and Dyn A 
(Berman et al. 2000). BDyn is a proteolytic product of PDYN containing one copy of Dyn 
A, Dyn B and two copies of Leu-Enk. Full-length BDyn was incubated for 30 minutes in 
WT, PC1-/+ and PC2-/+ mouse spinal cord S9 fractions and metabolites quantified by HPLC-
MS/MS. The rate of formation (vi) was determined using Equation 1. As shown in Figure 5, 
cleavage at paired and single basic sites were observed forming Dyn 1-19, Dyn 1-13, Dyn 1-
11 and Dyn 1-7. As expected, no trace of Dyn 1-9 was detected since PCs do not cleave when 
single or paired basic amino acids are followed by a Proline (P). The contribution of PC1 and 
PC2 in the degradation of BDyn is noteworthy. As shown in Figure 5, PC1 and PC2 mediate 
processing of BDyn to Dyn 1-19, but only PC1 appears to be significant for the formation of 
Dyn 1-11. No statistically significant differences were noted for Dyn 1-13 and Dyn 1-7. 
However, this does not mean that PC1 and PC2 are not involved in the formation of these 
metabolites but only suggest that they are not principal metabolites of BDyn since the 
enzymes active sites are largely saturated with BDyn. Rate of formation changes will be 
noticed only when substrate concentration saturates or the enzymes active sites nearly 
saturates. Therefore, rate of formation differences for minor metabolites of BDyn produced 
by the same metabolic pathway can't be clearly observed. The stability of the enzyme-peptide 
complex is closely related with the enzyme structure. It plays a central role in defining the 
energetically favored binding cluster of the peptide into the active enzyme site (Sun and 
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Scott, 2010). As shown in silico, the structure of the binding cluster may lead to different 
metabolites or affect the rate of formation (Sun and Scott, 2010). Our results suggest that the 
formation of Dyn 1-19 and Dyn 1-11 is favored following the formation of the enzyme-
peptide complex. Interestingly, metabolites generated following the removal of basic amino 
acids from the C-terminal by carboxypeptidases were also impacted. Figure 6 reveals that 
rate of formation of Dyn 1-10, Dyn 1-6 and Leu-Enk in PC1-/+ mouse spinal cord S9 fractions 
is significantly hampered with some noticeable reduction in the formation of Dyn A (not 
statistically significant). Furthermore, Dyn A formation is reduced in PC2-/+ mouse spinal 
cord S9 fractions. These results clearly demonstrate that PCs regulate BDyn concentrations 
through C-terminal processing. Turnover kinetics of neuropeptides is important to describe 
the formation of all bioactive peptides that play an important role in synaptic transmission. 
As shown in Figure 5 and 6, proteolysis of BDyn leads to the formation of important opioid 
peptides, including specifically, Dyn A and Leu-Enk. BDyn is a precursor of Dyn A and has 
two copies of Leu-Enk encoded in its primary sequence. More specifically, the interaction of 
Dyn A with κ-opioid receptors located at the presynaptic terminals inhibits the release of SP 
and therefore plays a central role in alleviating pain. Proteolytic processing of BDyn leads to 
the formation of Leu-Enk, an agonist of the δ-opioid receptors (Chen et al., 2007; Fichna et 
al., 2007). The activation of δ-opioid receptors by endogenous enkephalins mediates 
analgesic effects. Both peptides have a fundamental function in the endogenous opioid 
system. As a consequence, even partial inhibition of PC1 or PC2 may impair the endogenous 
opioid system.   
3.6 Contribution of PC1 and PC2 in Dyn A C-terminal processing 
Spinal concentration of Dyn A was reported to increase in patients suffering of acute and 
chronic pain (Wang et al., 2001). As mentioned before, Dyn A inhibits pain transmission 
since it impedes SP release in the spinal cord (Zachariou and Goldstein, 1997). Also, it can 
affect nociceptive synaptic transmission by blocking the calcium channels (Werz and 
Macdonald, 1984; Werz and Macdonald, 1985). Others have indicated that dynorphins act as 
pronociceptive peptides by activating non-opioid receptors (Lai et al., 2006; Tang et al., 
2000) and participate in the generation of chronic pain (Wang et al., 2001). Thus, 
understanding proteolytic regulation of Dyn A can be insightful on the pathophysiology of 
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nociceptive pain and potential new strategies for treatment. Full-length Dyn A was incubated 
for 30 minutes in WT, PC1-/+ and PC2-/+ mouse spinal cord S9 fractions and metabolites 
quantified by HPLC-MS/MS. The rate of formation (vi) was determined using Equation 1. 
Figure 7A distinctly demonstrates that PC1 is involved in the proteolysis control of Dyn A 
in the spinal cord. PC1 clearly mediates the processing of Dyn A to Dyn 1-13, Dyn 1-11 and 
Dyn 1-7, metabolites that resulted from a cleavage at paired or single basic residues. 
Similarly to BDyn results, Dyn A metabolites generated following the removal of basic 
amino acids from the C-terminal by carboxypeptidases were also impeded. As illustrate in 
Figure 7B, the rate of formation (v1) of Dyn 1-10, Dyn 1-6 and Leu-Enk was significantly 
hampered in PC1-/+ mouse spinal cord S9 fractions. To a much lesser extent, the rate of 
formation (v1) of Dyn 1-10 and Dyn 1-6 was significantly reduced in PC2-/+ mouse spinal 
cord S9 fractions. Again, interestingly, the proteolysis controls of Dyn A generated Leu-Enk, 
another important opioid peptide mediating potent painkilling effects (Holden et al., 2005; 
Akil et al., 1997). Thus, proteolysis regulation of BDyn and Dyn A play an important role in 
the control of endogenous concentrations but also play a significant role in the production of 
peptide fragments with opiate-like properties with strong antinociceptive effects. 
Pharmacological manipulation of PC1 and PC2 may therefore have a profound impact on the 
endogenous pain-relieving mechanisms.  
 
 
4. Conclusion 
In neuronal cells, almost all neuropeptides are produced through endoproteolysis specifically 
at C-terminal pairs of basic residues during their transport along the secretory pathway. 
Interestingly, it is recognized that proneuropeptides are cleaved using a cell-specific 
mechanism by members of the family of calcium-dependent subtilisin-like endoproteases 
(Steiner et al., 1998; Seidah et al., 1999; Hook et al., 2008). PC1 and PC2 are predominantly 
expressed in neural cells and our results suggest they play a central role in the proteolysis 
controls of endogenous BDyn and Dyn A levels generating important peptide metabolites. It 
is important to recognize that physiologically, the differential expression of PC1 and PC2 in 
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different neuroendocrine cells and neurons may generate varied mixtures of BDyn and Dyn 
A metabolites since observed metabolic products are intimately related to the thermodynamic 
stability of the enzyme-peptide complexes and the turnover number (kcat) is associated with 
the enzyme concentration. Several dynorphins and enkephalins play a central role in pain 
modulation and inhibition and the proteolytic regulation of endogenous dynorphins has a 
profound impact on the pathophysiology of pain. The pronociceptive tachykinin system (SP-
NK1) and the analgesic opioid systems are important for normal pain sensation and these 
systems strongly interact together (Saidi and Beaudry, 2015). Our results clearly demonstrate 
that both PC1 and PC2 are involved in the proteolysis regulation of BDyn and Dyn A with a 
more important role for PC1. Interestingly, PCs may also play a role in the proteolytic 
processing of the protachykinin-1 protein (Saidi et al., 2015) and therefore, be directly or 
indirectly involved in the formation of SP, a neuropeptide playing a critical role in 
nociceptive transmission. These observations may have insightful impact on our basic 
knowledge on the proteolytic regulation of neuropeptides in the central nervous system and 
for future analgesic drug developments. 
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Table 1. Summary of peptide quantification parameters used for HPLC-MS/MS analysis 
and post processing MRM 
 
Peptides Sequences Precursor ions Product ions Collision energy (%) 
BigDynorphin YGGFLRRIRPKLKWDNQKR
YGGFLRRDFKVVT 
570 (z = 7) 645.3 (b316+) 
561.4 (a276+) 
45 
Dynorphin 1-19  YGGFLRRIRPKLKWDNQKR 487 (z = 5) 629.9 (b153+ ) 
564.0 (z184+) 
45 
Dyn A YGGFLRRIRPKLKWDNQ 716 (z = 3) 944.2 (b152+) 
630.1 (b153+) 
45 
(d5 )Dyn A YGGF(d5) 
LRRIRPKLKWDNQ 
719 (z = 3) 947.2 (b152+) 
631.6 (b153+) 
45 
Dyn 1-13 YGGFLRRIRPKLK 
 
535 (z = 3) 493.0 (c123+) 
449.0 (b113+) 
35 
(d5 )Dyn 1-13 YGGF(d5) LRRIRPKLK 537 (z = 3) 494.4 (c123+) 
451.0 (b113+) 
35 
Dyn 1-11 YGGFLRRIRPK 
 
682 (z = 2) 618.0 (c102+) 
560.3 (b92+) 
35 
(d5 )Dyn 1-11 YGGF(d5) LRRIRPK 684 (z = 2) 620.5 (c102+) 
563.0 (b92+) 
35 
Dyn 1-10 YGGFLRRIRP 618 (z = 2) 560.4 (b92+) 
539.4 (b5) 
35 
(d5 )Dyn 1-10 YGGF(d5) LRRIRP 621 (z = 2) 563.0 (b92+) 
541.9 (b5) 
35 
Dyn 1-9 YGGFLRRIR 570 (z = 2) 491.42 (c82+) 45 
Dyn 1-7 YGGFLRR 435 (z = 2) 694.5 (b6) 
631.6 (z5) 
45 
(d5 )Dyn 1-7 YGGF(d5) LRR 437 (z = 2) 699.5 (b6) 
636.5 (z5) 
45 
Dyn 1-6 YGGFLR 
 
357 (z = 2) 549.5 (y5) 
492.4 (y4) 
35 
(d5 )Dyn 1-6 YGGF(d5)LR 
 
359 (z = 2) 554.4 (y5) 
497.5 (y4) 
35 
Leu-Enk YGGFL 556 (z = 1) 425.3 (b4) 
397.3 (a4) 
35 
(d5 )Leu-Enk YGGF(d5)L 561 (z = 1) 430.3 (b4) 
402.3 (a4) 
35 
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Table 2. Summary of the most significant C-terminal processing BDyn peptide metabolites 
detected using high-resolution accurate mass spectrometry 
 
 
 
 
 
 
 
 
Peptides Sequences Charge 
states z 
Theoretical 
mass 
Observed 
mass 
Δm 
(ppm) 
BigDynorphin YGGFLRRIRPKLKWDNQKRYG
GFLRRDFKVVT 
+7 569.9008 569.9009 0.18 
Dynorphin 1-19  YGGFLRRIRPKLKWDNQKR +5 487.0847 487.0893 
 
1.64 
Dyn A YGGFLRRIRPKLKWDNQ +3 716.4043 716.4033 - 1.40 
 
Dyn 1-13 YGGFLRRIRPKLK +3 535.3351 
 
535.3349 - 0.37 
Dyn 1-11 YGGFLRRIRPK +2 681.9095 
 
681.9094 - 0.15 
Dyn 1-10 YGGFLRRIRP +2 617.8620 
 
617.8618 
 
- 0.32 
Dyn 1-7 YGGFLRR +2 434.7430 
 
434.7433 
 
0.69 
Dyn 1-6 YGGFLR +2 356.6925 
 
356.6923 
 
- 0.56 
Leu-Enk YGGFL +1 556.2766 556.2761 0.90 
Dyn B YGGFLRRDFKVVT +3 524.2999 524.2994 - 0.95 
Dyn 12-32 LKWDNQKRYGGFLRRDFKVVT +5 528.6994 528.6998 0.76 
Dyn 14-32 WDNQKRYGGFLRRDFKVVT +5 480.4636 480.4636 0.00 
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Table 3. Summary of the most significant C-terminal processing Dyn A peptide 
metabolites detected using high-resolution accurate mass spectrometry 
 
 
  
Peptides Sequences Charge 
states z 
Theoretical 
mass 
Observed 
mass 
Δm 
(ppm) 
Dyn A YGGFLRRIRPKLKWDNQ +3 716.4043  716.4037 - 0.84 
Dyn 1-13 YGGFLRRIRPKLK +3 535.3351 535.3350 - 0.19 
Dyn 1-11 YGGFLRRIRPK +2 681.9095 681.9092 - 0.44 
Dyn 1-10 YGGFLRRIRP +2 617.8620 617.8616 - 0.65 
Dyn 1-7 YGGFLRR +2 434.7430 434.7429 - 0.23 
Dyn 1-6 YGGFLR +2 356.6925 356.6922 - 0.84 
Leu-Enk YGGFL +1 556.2766 556.2762 - 0.72 
Dyn 14-17 WDNQ +1 562.2256  562.2255 -0.18 
Dyn 12-17 LKWDNQ +2 402.2060 402.2058 -0.50 
Dyn 8-17 IRPKLKWDNQ +3 433.2507 433.2505 -0.46 
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Figure Legends 
 
Figure 1. Prodynorphin (PDYN) processing by proprotein convertases (PC1 and PC2). 
Dynorphins have several paired and single basic amino acid cleavage sites and based on the 
sequence, various processing intermediates can be derived leading to dynorphin 1-19, 
dynorphin 1-13, dynorphin 1-11, dynorphin 1-7 and other active neuropeptides. Moreover, 
Dynorphin A encode one copy of Leu-Enk (YGGFL) suggesting, it could be an important 
proteolytic product. 
Figure 2. . Product ion spectra (MS2) of dynorphins. MS/MS spectra were annotated based 
on the Roepstorff and Fohlman nomenclature. Product ions observed were compatible with 
the primary sequence of each peptide analyzed. 
Figure 3. Reconstructed ion chromatograms for targeted dynorphins. Reference standards 
(black) and incubated spinal cord (SC) S9 fractions were compared. Please note that at time 
0, no metabolites were observed.  
Figure 4. Evaluation of the metabolic stability of BDyn and Dyn A in mouse spinal cord S9 
fractions. The degradation of full-length peptides occurred only with the presence of S9 
proteins and demonstrates that BDyn and Dyn A undergoes proteolytic processing in mouse 
spinal cord S9 fractions. 
Figure 5. Assessments of PC1 and PC2 involvement in the proteolysis of big dynorphin. 
Results suggest that PC1 and PC2 are involved in the proteolytic processing of big dynorphin 
leading to the formation of dynorphin 1-19 and dynorphin 1-11.  
Figure 6. Impact of PC1 and PC2 on the formation of other big dynorphin metabolites. The 
formation of dynorphin A, dynorphin 1-10, dynorphin 1-6 and Leu-Enk is severally impaired 
particularly in PC1-/+ spinal cord S9 fractions.  
Figure 7. Assessments of PC1 and PC2 involvement in the proteolysis of dynorphin A. (A) 
Illustrates the important role of PC1 in the formation of dynorphin 1-13, dynorphine 1-11 
and dynorphin 1-7. (B) The formation of dynorphin 1-10, dynorphin 1-6 and Leu-Enk is 
significantly reduced in PC1-/+ and PC2-/+ spinal cord S9 fractions. 
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GENERAL DISCUSS
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Determining complex molecular mechanisms involved in pain modulation is 
necessary for the understanding of the causes and the evolution of neuropathic and chronic 
pains. The endogenous opioid system might be a target through which new pain treatments 
could be designed. Current analgesic treatments induce analgesia by just masking the causes 
that generate pain. These treatments are principally based on the administration of opioid-
like drugs which act on opioid receptors leading to a rapid relief of pain. Even though their 
effects are potent and effective, lengthy treatments have shown to cause several side-effects 
(Gallagher and Rosenthal, 2008; Sindrup and Jensen, 1999). These side-effects include the 
formation of undesirable metabolic products and CNS plasticity problems that might change 
the normal stimulus-response characteristics (Woolf and Salter, 2000). Targeting events 
upstream of the endogenous opioid system and its regulation, could lead to a novel strategy 
through which other antinociceptive strategies could be designed.  
Dynorphins are an important family of endogenous opioid peptides, which play an 
essential role in pain modulation as well as in the progression of various diseases such as 
inflammation due to pathogenic infections (Seidah and Prat, 2012). Nevertheless, the 
metabolic pathway and the physiological role of dynorphins are still unclear. Dyn A is known 
to be one of the most abundant dynorphin found in the mammalian CNS, and it induces potent 
analgesic effects at spinal levels (Kuner, 2010; Mika et al., 2011). The metabolic stability of 
endogenous dynorphin peptides is an important factor to take into consideration since it 
regulates the duration of dynorphins-induced analgesia. Thus, if high levels of endogenous 
Dyn A are maintained by prolonging its metabolic stability, it could lead to long-lasting and 
effective antinociception. 
Endogenous levels of dynorphins are regulated by the action of PCs, which are 
involved in the endoproteolytic processing of the dynorphins precursor, PDyn (Berman et 
al., 2000; Day et al., 1998). Early studies suggest that the action of PC2 is needed for the 
formation of BDyn, Dyn A and Dyn B (Day et al., 1998), even though no studies on the role 
of PCs on BDyn and Dyn A metabolism have been reported. As a consequence, the metabolic 
stability and the potential metabolic products of BDyn and Dyn A still remains unclear.  
 
84 
 
 
 
1-Summary of results  
Experiments reported here were focused on the evaluation of the metabolic stability 
of BDyn and Dyn A in mouse spinal cord S9 fractions. The results show that the degradation 
of full-length peptides occurred only with the presence of S9 proteins, demonstrating that 
BDyn and Dyn A undergoes proteolytic processing when incubated in mouse spinal cord S9 
fractions. The designed HPLC-MS method allowed for the selective identification of several 
metabolites resulting from the enzymatic degradation of both precursors. In addition, by 
using isotope dilution as a quantification method, it was possible to quantify the metabolites 
and evaluate their relative rate of formation. Moreover, HRAM MS analyses were used to 
provide a second verification and to assess peptides identity with a mass accuracy within 2 
ppm.  
From the in vitro digestion of BDyn and Dyn A precursors, several dynorphin 
peptides were identified as products from C-terminal processing at basic positions of both 
precursors. The enzymatic degradation of BDyn lead to the generation of dynorphin peptides 
such as Dyn 1-19, Dyn 1-13, Dyn 1-11. The identification of their complementary fragment 
peptides, including Dyn B, Dyn 12-32, Dyn 14-32 supported those results and suggested that 
they are most likely primary cleavage products from BDyn. On the other hand, Dyn A 
processing was observed to generate Dyn 1-13, Dyn 1-11 and Dyn 1-7. Their respective 
complement fragments Dyn 14-17, Dyn 12-17 and Dyn 8-17 were also observed. BDyn and 
Dyn A processing pattern were compatible with PC1 and PC2 processing, showing a crucial 
processing role of these enzymes. Other dynorphin peptides, including Dyn A, Dyn 1-10, 
Dyn 1-6 and Leu-Enk were also identified. These peptides are considered as secondary 
metabolites and their formation is associated with the removal of C-terminal basic residues 
by CPE.  
To elucidate the role of PC1 and PC2 on BDyn and Dyn A processing, cellular S9 
fractions were isolated from WT, PC1(-/+) and PC2(-/+) mice and used to perform the in vitro 
digestion of the full-length precursor peptides. In order to assess differences on the 
expression of PC1 and PC2 between the 3 genotypes, the relative abundance of PC1 and PC2 
were quantified in the three cellular S9 fractions. The quantification was performed following 
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a bottom-up proteomic strategy and using high-resolution MS. The concentration of both 
enzymes on the S9 fractions isolated from the mutant mice were expressed as a relative 
concentration of the enzyme compared with the WT mice. The results revealed that the 
expression of PC1 and PC2 were significantly down-regulated, around 40% in the PC1-/+ and 
around 50% in the PC2-/+ S9 fractions respectively.  
The In vitro digestion of both precursors were then performed and the data obtained 
was statistically compared between the three genotypes. The presence of different PCs target 
cleavage points on BDyn sequence, including dibasic KR and RR and monobasic K and R 
positions, presents an opportunity to study differences on cleavage affinity of both enzymes 
for basic positions. Results generated from BDyn digestion clearly revealed an important 
contribution of both, PC1 and PC2, in precursors processing at KR dibasic residues. 
Interestingly, both enzymes show a similar affinity for this cleavage point but we can’t 
exclude that PC1 could compensate for the reduction of PC2 activity in cleaving dibasic 
residues when the former is absent and vice versa. On the contrary, cleavage at the dibasic 
RR position was not observed for PC2, and PC1 as shown by a non-significant affinity for 
this position. However processing at monobasic positions, K and R were shown to be 
completely regulated by PC1. On the other hand, those results were corroborated by the data 
obtained from the incubation of Dyn A with the S9 fractions. Dyn A presents one dibasic 
position of cleavage, RR, as well as K and R monobasic amino acids, all of them possible 
targets for PC1 and PC2 cleavage.  Surprisingly, the data obtained from Dyn A in in vitro 
digestion show that Dyn A degradation was completely governed by PC1 and that PC2 did 
not play a role in its processing. PC1 was observed to efficiently cleave at RR, K and R 
positions, being the enzyme responsible of the regulation of Dyn A. Moreover, the data 
suggest that PC2 did not compensate for the reduction of PC1 activity in cleaving these 
specific sites.  
 
2-Relevance of the observations  
PC1 and PC2 have been proposed to be involved in PDyn processing, leading to the 
generation of high molecular weight dynorphin peptides including BDyn. The generation of 
the peptides is the result of the proteolytic processing of dynorphins by PC1 and PC2, 
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cleaving mainly at dibasic KR amino acids, but also at R monobasic position. These early 
studies suggested that the action of PC2 is needed for the formation of most of the high 
molecular weight dynorphin peptides. PC2 is thus involved in long peptide processing at the 
monobasic and dibasic positions (Day et al., 1998; Berman et al., 2000). On the other hand, 
PC1 has been reported to be implicated in the processing of PDyn into high molecular weight 
peptides, but its contribution is significantly lower than PC2. The main cleavage sites for 
PC1 is at the KR paired amino acids (Berman et al., 2000). These results lead to the 
hypothesis that PC1 and PC2 might have a similar role in the processing of low molecular 
weight peptides such as BDyn and Dyn A. 
According to the proposed hypothesis in the present study, the results clearly show 
that PC1 and PC2 are also involved in the processing of BDyn and Dyn A. Furthermore, the 
KR paired amino acids found on BDyn sequence, were observed to be a targeted point of 
cleavage either by PC1 or PC2. Contrary to the data presented in previous studies, the affinity 
of both enzymes on KR processing sites were observed to be similar for both enzymes. 
Moreover, BDyn and Dyn A monobasic processing was observed to differ from previous 
results reported. Results shown here indicate that monobasic processing of BDyn and Dyn A 
was completely regulated by PC1 both at K and R positions. 
Taking earlier observations and the present results together, PC2 seems to be more 
active in cleaving large peptides, while PC1 appears to be more involved at processing 
smaller peptides. Affinity of enzymes for their respective substrates are mostly regulated by 
binding affinity. The formation of the enzyme-substrate complex is governed by the 
thermodynamic stability of the complex. Thus, steric hindrance is an important factor in the 
impairment of the cleavage process. PC1 is a protein consisting of 753 amino acids, whereas 
PC2 consist of 638 amino acids (Saidi et al., 2015). This suggests that the steric hindrance of 
PC1 cleaving large proteins might be greater than for PC2. This factor could be one reason 
that explains the different role and affinity of PC1 and PC2 depending on the size of the 
protein subject to cleavage.  
To confirm one of the previous hypotheses, it is important to point out the formation 
of Leu-Enk, a metabolic product resulting from the in vitro digestion of BDyn or Dyn A. 
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This observation demonstrates that Leu-Enk might be a metabolic product from PDyn in 
addition to PEnk. 
 
3-Implication of the results 
Endogenous antinociceptive system is governed by the levels of active opioid 
peptides. Dynorphins, enkephalins and endomorphins are some of those endogenous peptides 
which participate in the endogenous modulation of pain. Specifically, Dyn A is one of the 
major dynorphins found in mammalian CNS (Civelli et al., 1985; Dores et al., 1985; Tan-No 
et al., 1997). Dyn A is an endogenous ligand of KOR and MOR producing analgesic effects 
and significantly reducing neuronal activity (Mizoguchi et al., 2006). Other dynorphins such 
as Dyn 1-13, Dyn 1-11 or Dyn 1-6 have also been reported to mediate analgesia when they 
are directly injected into rats, even though the duration of their activity seems to be short-
lasting (Goldstein et al., 1979; Takemori et al., 1992; Reed et al., 2003). This observation 
might be caused, in addition to the differences in their affinities and kinetics for binding 
KOR, by a lower stability of short peptides compared to larger ones. The smaller the peptide, 
the shorter is its stability. The presence of degrading enzymes in neuronal cells make active 
opioid peptides to tend to degrade rapidly (Mosnaim et al., 2008).  
The high abundance of Dyn A might be due to its high metabolic stability. That means 
that even though the potency of other dynorphins might be higher than Dyn A, their absolute 
effect on producing analgesia could be more significant. The above observation shows that 
Dyn A is an important dynorphin peptide regarding its activity and stability. 
The observations extracted from the present experiments clearly show that PC1 
regulates the metabolism of Dyn A. Therefore, controlling the activity of PC1 can result in 
prolonged stability of Dyn A resulting in a more active modulation of pain through 
endogenous mechanisms. Also, PC1 is also involved in the endoproteolysis of protackykinins 
(Saidi et al., 2015) and partial inhibition can lead to a significant reduction of SP levels in 
the synaptic gap leading to a reduction of SP-NK1 interactions impeding the pronociceptive 
effect of SP. However, it will be useful to perform an exhaustive phenotyping study on PC1-
/+ mice using validated pain models in order to elucidate if a reduction of PC1 activity is 
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sufficient to significantly reduce pain behavior. It is important to note that completely 
alleviate pain is undesired since it may further aggravate injuries.   
 
4-Limitations 
PC1 and PC2 participate in the synthesis of several endogenous opioid peptides from 
its respective precursors such as Enkephalins (Breslin et al., 1993; Johanning et al., 1996 and 
1998) and endorphins (Zhu et al., 2002; Miller et al., 2003). Those studies also converge on 
the fact that PC2 appears to be more capable of generating active opioid units from PEnk and 
POMC than is PC1. This premise supports the concept that even if the activity of PC1 is 
partially inhibited, the action of PC2 might lead to an efficient formation of active opioid 
peptides such as enkephalins and endorphins, in addition to favoring the stability of certain 
opioids such as Dyn A. 
Even if PC1 were to be inhibited in order to prolong the activity of Dyn A, its 
inhibition could result in the lack of processing of protachykinin-1, the neuroprecursor that 
encodes SP. SP is a neurotransmitter that plays a central role in nociceptive transmission in 
the CNS. PC1 and PC2 have been observed to be equally involved in protachykinin-1 
processing (Saidi et al., 2015). This fact suggests that a partial inhibition of PC1 or PC2 
would lead to a reduction in the amount of active SP. As a consequence of the reduction in 
the release of SP, the endogenous opioid system could not be activated. 
 
 
 
 
 
 
 
 
 
 
CONCLUSIONS
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The in vitro digestion experiments performed on the present study using cellular S9 
fractions, demonstrate that PC1 and PC2 are crucial for the endoproteolytic processing of 
BDyn and Dyn A. Moreover, the results generated from WT, PC1(-/+) and PC2(-/+) mice have 
shown that PC2 is involved in the processing of BDyn through the cleavage at dibasic KR 
positions leading to the generation of Dyn 1-19. However, PC2 cleavage at monobasic 
positions was not observed. On the other hand, PC1 was able to cleave at KR dibasic 
positions with a similar efficiency as PC2. Interestingly, PC1 was also observed to cleave at 
RR dibasic positions and at monobasic R and K amino acids. Thus, PC1 can lead to the 
formation of Dyn 1-19, Dyn 1-13, Dyn 1-11, Dyn 1-7 and Dyn 1-6. In addition, other 
dynorphin peptides were also identified from the processing of BDyn and Dyn A, including 
Dyn A from BDyn, and Dyn 1-10 and Leu-Enk from either BDyn or Dyn A. These peptides 
are most probably metabolic products from the removal of terminal basic amino acids by 
CPE from Dyn 1-19, Dyn 1-11 and Dyn 1-6 respectively.  
Our results establish that PC1 is involved in the proteolytic control of Dyn A, since 
its processing is exclusively regulated by cleavage at mono basic residues (K or R). Contrary, 
PC2 was not observed to participate on the metabolism of Dyn A, but its activity is important 
for the formation of Dyn 1-19 from BDyn, which leads to the generation of Dyn A through 
the subsequent action of CPE.  
In addition, the present study also establish, for the first time, that Leu-Enk is a 
significant metabolic product of BDyn and Dyn A, showing another metabolic route of 
formation in addition to PEnk. 
Although further studies representing physiological conditions will be needed to 
substantiate the role of PC1 and PC2 on the processing of further proneuropeptides and 
prohormones, these findings suggest that a partial inhibition of the activity of PC1 might 
favor the maintenance of high endogenous levels of active opioid peptides such as Dyn A. 
Thus, the results presented could represent the first step towards an important advancement 
on the design of new analgesic drugs.  
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